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BL1   Basal-like 1  
BL2   Basal-like 2 
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°C    Degree Celsius  
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CSC   Cancer stem cell 
DAPI    4',6-diamidino-2-phenylindole  
DEPC    Diethylpyrocarbonate  
DMEM    Dulbecco's modified eagle's medium  
DMSO    Dimethyl sulfoxide DNA deoxyribonucleic acid  
dNTP    Deoxyribonucleotide  
DTT    Dithiothreitol  
EDTA    Ethylenediaminetetraacetic acid  
EMT   Epithelial to mesenchymal transition 
EtOH    Ethanol  
EZH2   Enhancer of zeste 2 
FACS    Fluorescence-activated cell sorting  
FDA   Food and Drug Administration 
FDR    False discovery rate 
GSEA   Gene set enrichment analysis 
H&E   Hematoxylin and eosin 
H3   Histone 3 
HAT    Histone acetyltransferase 
HDAC   Histone deacetyltransferase 
HDACi   HDAC inhibitor 
H3K27ac   Histone 3 acetylated at position lysine 27  
H3K27me3   Histone 3 trimethylated at position lysine 27  
IAA    Iodacetamide  
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NGS   Next generation sequencing 
NP-40    Nonidet P40  
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PBS-T    Phosphate buffered saline with tween-20  
PcG   Polycomb group proteins 
PCR    Polymerase chain reaction 
PRC2   Polycomb repressive complex 2 
PTM   Post-translational modification 
RBBP7   Retinoblastoma-binding protein 7 
RNA    Ribonucleic acid 
RNA-seq  RNA sequencing 
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RT    Room temperature  
RT-PCR/qPCR   Reverse transcription PCR  
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SDS-PAGE   Sodium dodecylsulfate polyacrylamide gel electrophoresis 
siRNA   Small interfering ribonucleic acid  
SUZ12   Suppressor of zeste 12 protein homolog 
siRNA    Small interfering RNA  
TEMED   Tetramethylethylenediamine  
TF   Transcription factor 
Tris    Tris(hydroxymethyl)aminomethane  
TSS   Transcriptional start site 
TNBC   Triple negative breast cancer 
VIM   Vimentin 
WAP   Whey acidic protein 
WB    Western blot  
Wnt     Wingless and Int-1 





Triple negative breast cancer (TNBC) is one of the most challenging cancers 
to treat as, despite the initial response to chemotherapy, relapse occurs frequently. In 
this project, we focused on the mechanisms that allow TNBC cell survival under 
chemotherapy treatment. Phenotypic changes in TNBC cells such as gain of 
mesenchymal transition and stemness during genotoxic stress adaptation have been 
reported. Based on our data, CAF (Cyclophosphamide, Doxorubicin and 5-
Fluorouracil)-chemotherapy treatment in TNBC cells leads to downregulation of the 
Polycomb Repressive Complex containing the methyl transferase EZH2 
(PRC2/EZH2) and upregulation of Histone Deacetylases (HDAC4, -7 and -8).  
EZH2 is responsible for the gene silencing through H3K27me3 catalysis and is 
known as an invasiveness marker. It appears that EZH2 can have also anti-
tumorigenic function. We identified, among others, Nuclear factor of activated T cells 
(NFATc1), as a gene regulated by EZH2 loss upon chemotherapy treatment in TNBC 
cells, indicated epigenetic switch. NFATc1 showed H3K27me3 loss and H3K27ac 
gain upon chemotherapy, where H3K27ac works antagonistically to the repressive 
mark, H3K27me3. NFATc1 has been associated with drug resistance and its loss 
impairs proliferation, migration and mesenchymal properties in TNBC cells in vitro. 
Our results strongly indicate a negative regulation of EZH2 on NFATc1 expression, in 
vitro and in vivo. Additionally, in TNBC patient data, we observed that low EZH2 and 
high NFATc1 expression correlate with poor survival. Therefore, in patients showing 
low EZH2 expression in cancer, NFATc1 inhibition may represent an alternative 
treatment option. 
Furthermore, our preliminary studies on HDACs suggest that HDAC8 supports 
TNBC invasiveness, affecting cell growth and modulating EMT. Interestingly, selective 
HDAC8 inhibition sensitizes TNBC cells to chemotherapy. This provides a potential 
mechanism linking epigenetic adaptation and cancer state during TNBC 
chemotherapy resistance. 
In summary, this work demonstrates a previously unknown PRC2/EZH2 
function in TNBC, where its downregulation contributes to NFAT pathway changes 
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driving cancer progression. Hence, NFATc1 can be considered as potential 
PRC2/EZH2–dependent driver of TNBC invasiveness. Additionally, we identified 
HDAC8 and NFATc1 as an interesting targets for further investigation in potential anti-






1.1. Breast cancer 
According to the World Health Organization, breast cancer is the most common 
and most frequent diagnosed cancer among women causing a high cancer-related 
death rate (World Health Organisation, 2018). Breast cancer survival rates vary 
worldwide, where the highest cancer-related mortality occurs in developing countries 
(Ferlay et al., 2010). Despite scientific and diagnostic advancements leading to 
improved patient life quality, breast cancer remains a major cause of mortality 
(Lukong, 2017; World Health Organisation, 2018). Breast tumors are very complex 
and heterogeneous with a high diversity in gene expression patterns and pathological 
features. Based on the high-throughput transcriptomic analysis, breast tumors are 
classified into major molecular subtypes (Perou et al., 2000). These are Luminal A, 
Luminal B, human epidermal growth factor receptor 2 (HER2)-positive and triple-
negative breast cancer (TNBC) (Figure 1) (Perou et al., 2000; Vallejos et al., 2010). 
The TNBCs account for 15- 20% of breast tumors. HER2-positive account for 10- 
15%, Luminal B for 20% and Luminal A for 40% of breast cancer cases (Metzger-
Filho et al., 2013). Breast cancer can be further categorized into subset, which based 
on three common immunohistochemical and targetable breast cancer biomarkers, the 
hormone receptors: estrogen receptor (ER), progesterone receptor (PR) and HER2.  
The treatment of breast cancer varies according to the subtype.  TNBC, as its 
name suggests, does not express any of these receptors. It is not responsive to target 
therapies against hormone receptors and HER2 receptor, therefore TNBC has the 
worst prognosis among breast cancer patients. The treatment of breast cancer varies 
according to the subtype. Local therapies include surgical resection and/or radiation 
(Matsen & Neumayer, 2013). Patients with non-metastatic, hormone receptor-positive 
breast cancer (Luminal A/B) receive hormone therapy, also called endocrine therapy 
(Wong et al., 2012). To minimize the possibility of metastasis, surgery may be followed 
by adjuvant therapy, as additional to primary treatment (Dhankhar et al., 2010). 
Patients presenting metastasis are treated with chemotherapy alone or in combination 
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with targeted therapies (Chacón López-Muñiz et al., 2019; Mayer & Burstein, 2007). 
Patients with HER2-positive cancers can receive trastuzumab/lapatinib treatment to 
block HER2 in combination with chemotherapy. Overall, Luminal A/B and HER2-
positive present better treatment options. On the other hand, TNBC, as its name 
suggests, is not responsive to target therapies against hormone receptors and the 
HER2 receptor, therefore non-resectable TNBC patients are treated with 




Figure 1:  Breast cancer molecular subtypes presenting cancer occurrence, receptor expression, 
histologic grade (I-III), prognosis indicating chance of patient survival  (poor- good) and therapy 
response indicating treatment option (chemotherapy, trastuzumab, endocrine therapy).  (modified from 
Wong et al., 2012). 
 
1.1.1. Triple-negative breast cancer in patients 
TNBC shows high incidence in young (<40 years old) African-American or 
Hispanic patients. These are often diagnosed at late cancer stage with a tendency to 
metastasize to lungs and brain (Morris et al., 2007; Sihto et al., 2011; Trivers et al., 
2009). TNBC is the most aggressive breast cancer subtype correlating with poorer 
prognosis and  a higher level of recurrence, mitotic rate, grade and tumor size than 
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non-TNBC subtypes (Figures 1 and 2) (Gonçalves et al., 2018; Hirukawa et al., 2018). 
Additionally, it was shown that TNBC patients run a higher risk of having early 




Figure 2: 5-year overall survival in TNBC and non-TNBC patients, 62.1% TNBC, 80.8% for non-
TNBC cases ( (P <0 .001) (Gonçalves et al., 2018). 
 
1.1.2. Molecular characteristics of TNBC 
TNBCs are defined by the lack of ER, PR and HER2, (Perou et al., 2000; Toft 
& Cryns, 2010). Additionally, 80% of TNBCs harbor TP53 mutations, a percentage 
that is much less in other subtypes. Other features of this subtype include loss of RB1, 
BRCA1 inactivation and high levels of AKT3 and MYC (Koboldt et al., 2012). TNBC is 
a very heterogeneous disease and is classified into the following subgroups: basal-
like 1 and 2 (BL1 and BL2), immunomodulatory (IM), mesenchymal (M), 
mesenchymal-like (MSL) and luminal androgen receptor-positive (LAR) (Lehmann et 
al., 2011).   
 Figure 3 provides an overview about the most enriched pathway signature for 
each TNBC subtype with potential inhibitors. For instance, BL1 is associated with cell 
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cycle, proliferation, DNA damage response pathways. Therefore, for instance the 
inhibitor of Poly (ADP-ribose) polymerase (PARP), which plays a role in DNA damage 
response, was one of the proposed drugs for this subgroup (Robson, 2011). It is 
known that BRCA1 mutation, among others, associates with cancer progression and 
is highly correlated with the basal-like TNBC subgroup (Haffty et al., 2019). BRCA is 
responsible for the repair of double-stranded DNA breaks via homologous 
recombination (HR). BRCA1 mutations cause DNA repair errors leading to genomic 
instability and carcinogenesis (Buisson et al., 2010). It was shown that BRCA1-
deficient tumors seem to be sensitive to PARP inhibitors alone and in combination 
with cisplatin (Rottenberg et al., 2008). Using PARP inhibitors in BRCA-deficient cells 





Figure 3: Drug classes in TNBC subtypes such as basal-like 1 and 2 (BL1 and BL2), 
immunomodulatory (IM), mesenchymal (M), mesenchymal-like (MSL) and luminal androgen receptor 
(LAR). Each dot represents one drug with its size corresponding to its rank position. Drug classes were 
derived into FDA New Drug Application (NDA) and GenEx-TNBC drug target profiles (Wathieu et al., 
2017). 
 
BL2 is associated with glycolysis, gluconeogenesis, angiogenesis and growth factor 
signaling pathways like EGF, NGF, MET and Wnt/β-catenin (Shaw et al., 2010). The 
immunomodulatory subgroup displays a robust immune cell response through 
immune activation and immunological infiltration. The LAR subgroup partially shares 
the gene expression profile with TNBC, but also overlaps with HER-2 positive cancer 
(Wathieu et al., 2017). In the mesenchymal-like and mesenchymal stem-like TNBC 
subgroups, characteristic pathways correspond to the epithelial to mesenchymal 
transition (EMT), Wnt/β-catenin, TGF-β and PI3K/AKT/mTOR pathways (Massihnia 
et al., 2016). Taken together, TNBC subgroups are variable in gene expression 
signatures and respond differentially to particular chemotherapy agents dosage, 
combinations and treatment cycles, such that TNBC treatment remains largely 
unsuccessful (Oleg Gluz et al., 2008).  
1.2. Chemotherapy resistance, EMT and stemness 
In addition to surgery and radiation, chemotherapy is a common therapeutic option 
for many cancers. Many TNBC patients are better responders to chemotherapy in 
comparison to non-TNBC patients. It was reported that patients treated with adjuvant 
chemotherapy showed a 52% increase of survival than those treated with neoadjuvant 
chemotherapy (Echeverria et al., 2019). Consequently, apart from surgery, targeted 
therapy followed by chemotherapy can be a potential strategy to combat TNBC. The 
most common drugs used for chemotherapy treatments are intercalating agents, 
anthracyclines (epirubicin or doxorubicin), alkyling agents cross-linking within DNA 
resulting in mutations (cylophosphamide) and antimetabolites like the  pyrimidine 
antagonist 5-fluorouracil (5-FU) or platinium-based agents (Kashiwagi et al., 2011; 
Sikov et al., 2015). TNBC resistance to chemotherapy is a major challenge in the clinic 
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and there is a need to develop targeted treatments in addition to the conventional 
therapies described (William, 2008).  
Resistance can emerge due to genetic alterations, where specific mutations 
can make cells insensitive to drug treatments. For example, loss of function TP53 
allows cells to evade cell death and continue proliferation (Luqmani, 2005). 
Environment mediated-drug resistance also plays a pivotal role during treatment, fo 
example, cancer stem cells (CSCs) can scavenge chemotherapy by expressing major 
ABC transporters (Dean, Fojo, & Bates, 2005).  
Cancer stem cells are defined by three features such as their capacity to 
differentiate according to their hierarchical state, their self-renewal property to 
maintain stem cell population and their homeostasis between differentiation and self-
renewal, according to environmental stimuli (Dalerba, Cho, & Clarke, 2007).  The 
cancer stem cell model suggests that hierarchically organized cells display distinct 
tumorigenic and metastatic capacities generating tumor cell heterogeneity (Bonnet & 
Dick, 1997; Shackleton et al., 2009). CSCs display stem-like features, slow growth 
rate and are involved in primary or acquired chemotherapy or radiotherapy resistance 
(Lajtha, 1967; Takebe et al., 2015). Additionally, aldehyde dehydrogenase (ALDH) 
activity is reported as a cell feature strongly correlated with self-renewal capacity 
(Marcato et al., 2011).  
Recent studies on patient-derived xenografts (PDX) with TNBC showed the 
survival of residual cancer cells upon doxorubicin/cyclophosphamide treatments due 
to activated signaling pathways protecting cancer cells (Echeverria et al., 2019; 
Hutchinson et al., 2018). PDX models resistant to neoadjuvant chemotherapy 
treatment revealed that residual cancer cells displayed unique histological and 
transcriptomic features in comparison to untreated tumors. Due to the reversible 
nature of drug-tolerance, tumors can overcome chemotherapy without clonal selection 
(Echeverria et al., 2019). Cancer cells are able to adapt to a changing environment 
and stress insults by gene expression reprogramming. One way in which this can 
occur is that cells undergo epithelial to mesenchymal transition (EMT). This process 
is reversible and mesenchymal cells have the capacity to transition back to the 
epithelial state (MET), reflecting the plasticity of cancer cells (Figure 4). Mesenchymal 
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cells with higher expression of VIMENTIN (VIM), SNAI1, N-CADHERIN (N-CDH) have 
weak cell-to-cell contact and a greater invasion and migration potential. In contrast, 
epithelial cells show prominent expression of E-CADHERIN (E-CDH) or EPITHELIAL 
CELL ADHESION MOLECULE (EPCAM) (Berx et al., 1995). SNAI1, a zing-finger 
protein, is a transcriptional repressor that regulates E-CDH in breast cancer, among 
others (Blanco et al., 2002; Paznekas et al., 1999). During carcinogenesis, E-CDH 
can be repressed via epigenetic modulation or a loss of function mutation (Hennig et 
al., 1995). EMT can be induced via HIF-1α, Wnt/β-catenin, c-MET and TGF-β (Bladt 
et al., 1995; Teng et al., 2014; Zhao et al., 2011). EMT was extensively described in 
the literature, showing that it is not sufficient for spontaneous breast cancer metastasis 
but is one of the mechanisms supporting cancer progression (Lou et al., 2008; Thiery, 
2002). Interestingly, studies on sarcomatoid carcinoma consisting of mixed 
phenotypes of breast carcinoma and sarcoma, showed that two cancer cell types do 
not derive from stem cells of epithelial and mesenchymal origin but only from one 
epithelial cell. It could suggest that EMT was involved in cancer cell plasticity (Thiery, 
2002). It was shown that the EMT program is associated with aggressiveness and 
metastasis in basal-like carcinoma (Ye et al., 2017). The EMT process can induce 
stem cell differentiation with reduced proliferation and the ability for therapeutic 
resistance. Standard chemotherapies lead to EMT activation where cancer cells can 
quickly adapt and overcome hostile environments promoting  tumor cell survival and 









Figure 4: Epithelial to mesenchymal transition (EMT) and reversed mesenchymal to epithelial transition 
(MET).  (A) Scheme of phenotypical and physiological changes during EMT including distinction in cell 
junction, polarity, cytoskeletal and protein rearrangement. (B) Invasive, tumorigenic and resistance 




1.2.1. The WAP-T mouse model to study resistance to chemotherapy, in vivo 
and in vitro. 
 The WAP-T mouse model was engineered to investigate mammary carcinoma 
cell properties,  (Schulze-Garg et al., 2000). Immune-competent WAP-T mice mimic 
the clinical situation of basal-like TNBC subtypes in humans (Wegwitz et al., 2010). 
Mammary carcinogenesis in these mice is driven by the activation of a transgene, the 
simian virus 40 (SV40), under the control of the whey acidic protein (WAP) promoter. 
WAP is important for lactation in mammary epithelial cells, thus resulting in the 
expression of SV40 only in mammary cells (Hennighausen et al., 1990). SV40 large 
T antigen and small t antigen bind and suppress the tumor suppressors p53 and pRb 
inducing tumorigenic transformation (Kao et al., 1993).  
 To investigate the behavior of TNBC cells, a parental G-2 (pG-2) cell line was 
used. pG-2 (in the publications indicated as G-2 cells) are WAP-T mice-derived cells, 
displaying high heterogeneity, epithelial-mesenchymal plasticity (EMP) and stem-like 
features. Hence, this system is considered as a self-proliferating mammary carcinoma 
system (Maenz et al., 2015; Wegwitz et al., 2010). It was shown that treatment with 
selected cytotoxic agents like Cyclophosphamide, Doxorubicin (Adriamycin) and 5-
Fluorouracil (CAF) also kills the vast majority of these cells. However, a small 
remaining pool of cells representing cells with a more aggressive and invasive 
phenotype was observed (Figure 5). This is in accordance with previous findings, 
where tumors formed from the transplantation of pG-2 cells into WAP-T mice, 
responded positively to CAF-chemotherapy. However, one round of CAF treatment 
was not sufficient to eliminate all cancer cells. Further analysis showed a great 
number of mesenchymal cells among disseminated tumor cells in comparison to 
untreated mice (Jannasch et al., 2015). Therefore, cancer cell plasticity represents a 
mechanism that can promote chemotherapy resistance. Interestingly, as described 
previously, cell plasticity can be mediated by reprogrammed gene transcription, which 
in part is regulated by epigenetic alterations. The tight regulation of epigenetic and 
transcriptional processes in the development of therapy resistance is essential and 




                               
 
Figure 5: Optimization of CAF-chemotherapy treatment in pG-2 cells. (A) Proliferation curves of pG-2 
cells treated with different chemotherapy concentrations: 1/2, 1/16, 1/32, 1/64, 1/128, where 1 
represents concentrations 10 µg/ml Cyclophosphamide, 0.5 µg/ml Doxorubicin and 10 µg/ml 5-
Fluorouracil (CAF). Cells confluence was measured everyday using the Celigo® cell cytometer and 
normalized to results at day 0. (B) Crystal violet staining of pG-2 cells at the end of the experiment 
followed by CAF-chemotherapy treatment (Schmidt, 2016). 
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1.3. Epigenetic modifications 
1.3.1. Chromatin compaction  
Within the nucleus of eukaryotic cells, DNA is tightly coiled around histone 
octamers, composed of H2A, H2B, H3 and H4, resulting in a DNA-nuclear protein 
complex called chromatin (Arents, 1991; Luger, 1997). Chromatin can be organized 
in a more open structure, called euchromatin or highly condensed one, called 
heterochromatin (Figure 6) (Jenuwein & Allis, 2001). Although high DNA compaction 
allows storing huge amount of genomic information in the nucleus, the access of 
factors regulating chromatin dynamics is limited due to the compaction. The structure 
and dynamics of chromatin is associated with gene expression regulation which 
determines the biological state of a given cell. Epigenetics involves mechanisms 
altering transcription of genes without changing the DNA sequence, regulating 
developmental paths initiating tissue-specific gene expression and therefore being 
crucial in cell fate determination (Reik, 2007; Waddington, 1957). 
 
Figure 6: Model of euchromatin and heterochromatin with histone tail modifications; acetylation (Ac) 
and methylation (Me) (modified from Jenuwein & Allis, 2001). 
 
 
1.3.2. Histone posttranslational modifications 
Histone tails harbor several post-translational modifications (PTMs), such as 
acetylation, methylation, phosphorylation, sumoylation and ubiquitylation. The N-
terminal histone tails harbor a positive charge with a tendency to link to negatively 
charged DNA. Adding an acetyl group (acetylation) neutralizes the charge resulting in 
chromatin relaxation (Figure 5) allowing the euchromatin structure to become more 
accessible for transcription factors inducing transcription. The opposite effect occurs 
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upon adding a methyl group leading to decreased recruitment of DNA binding proteins 
that promote transcription (Jenuwein & Allis, 2001).  
 Proteins known as “writers”, “erasers” and “readers” are responsible for adding, 
removing and recognizing particular post-translational histone modifications, 
respectively (Figure 7) (Audia & Campbell, 2016). Epigenetic writers can be histone 
acetyltransferases (HATs) or histone methyltranferases (HMTs). Protein arginine 
methyltransferases (PRMTs) and protein lysine methyltransferases (KMTs) have the 
capacity to transfer a methyl group from the cofactor S-adenosylmethionine, called 
SAM to the arginine or lysine residues, respectively (Simõ-Riudalbas & Esteller, 
2015). Histone acetyltransferase can be reversed via histone deacetylases (HDACs). 
Histone methylation can be removed through the histone demethylases UTX-1 or 
JMJD3 (Agger et al., 2007). The bromodomain and extraterminal (BET) family 
including BRD2, BRD3, BRD4 and BRDT can bind to acetylated lysines on histone 
tails and further regulate the fate of the chromatin, playing roles in cell growth, 
chromatin remodeling and DNA damage (Dawson et al., 2011; Simõ-Riudalbas & 
Esteller, 2015). Histone PTMs can occur on the global or locus-specific level. For 
instance, H3K27me mark can encompass distal enhancers, proximal promoters 
(enrichment around the transcription start site (TSS) and gene bodies (Figure 7) 
(Young et al., 2011). A particular epigenetic mark occupancy can modulate 
transcription, via fine-tuning RNA polymerase II (RNAPII) recruitment to the promoter 
and/or enhancer region. In this case, H3K27me3 on  enhancers and promoters limits 





Figure 7: Histone writers, erasers, and readers. Posttranslational modifications (PTMs) on Histone 3 
(H3) tail (left) along the gene loci (enhancer, promoter, gene body). Histone marks are indicated in 
green (methylation) and blue (acetylation) for active genes and in red shading for silent genes. 
Examples of writers, erasers and readers are indicated on the right side (modified from Audia & 
Campbell, 2016).  
 
The most studied epigenetic marks with opposing functions are trimethylation 
of histone 3 at the position of lysine 27 (H3K27me3) and its acetylation (H3K27ac) 
(Figure 8). H3K27 methylation, in general, is responsible for maintaining the 
repression of specific target genes, while acetylation promotes chromatin relaxation 
and transcription activation. Therefore, H3K27me3 and H3K27ac are considered as 
a repressive and active mark, respectively. These chromatin modifications are 
involved in the molecular regulation of gene expression patterns and can determine 





Figure 8: Chromatin modifications on histone 3 tail. Acetylation (Ac), methylation (Me), phosphorylation 
(P) and ubiquitination (U) occur mostly in N-terminal K and R rich tails (modified from Parsons, 2014). 
 
1.3.1 The Polycomb Repressive Complex 2 
One of the most important transcriptional modulators are polycomb group 
proteins (PcG), playing a role in cell proliferation and differentiation (Antonysamy et 
al., 2013). Two main PcG complexes have been described, Polycomb repressive 
complex 1 (PRC1) and 2 (PRC2). PRC2 represses genes by catalyzing the 
trimethylation of histone 3 at lysine 27. The Chromobox protein (CBX) subunit of 
PRC1 recognizes H3K27me3 and another member of the PRC1, E3 ubiquitin-protein 
ligase (RING1A/B), ubiquitinates histone H2A on K119 residue (H2AK119) 
maintaining a repressed chromatin state (H2AK119ub) (Di Croce & Helin, 2013).   
14 
 
PRC2 takes part in many biological processes, from differentiation to stem-cell 
plasticity, including repression of numerous developmental regulators in embryonic 
stem cells (Boyer et al., 2006; Raphaël Margueron & Reinberg, 2011). Apart from 
EZH1/2, PRC2 consists of Suppressor of zeste 12 protein homolog (SUZ12), 
Embryonic ectoderm development protein (EED) and Retinoblastoma-binding protein 
(RbAp46/48, also known as RBBP4/7). Enhancer of zeste 1 and 2 (EZH1/2) are 
protein homologs forming similar PRC2 complexes (PRC1/EZH1, and PRC2/EZH2). 
However, the PRC2/EZH1 complex seems to have a lower enzymatic activity and, in 
contrast to EZH2, loss of EZH1 does not result in a global loss of di- or trimethylation 
of H3K27 (H3K27me2/3). Previous studies have shown that both EZH1 and EZH2 
repress transcription in vitro (Raphael Margueron et al., 2008). Additionally, Ezh1 is 
ubiquitously expressed, whereas Ezh2 expression is tightly associated with 
proliferating cells (Raphael Margueron et al., 2008). EZH2 is an essential PRC2 
member, requiring other PRC2 binding partners SUZ12, RBBP7 and EED to be active  
(Denisenko et al., 1998; Liu et al., 2015; Pasini et al., 2004).  
The canonical PRC2/EZH2 pathway leads to gene silencing that can be diverse 
among organisms and tissues. (Cao & Zhang, 2004; Gan et al., 2018). PRC2 proteins 
silence target genes upon binding to specific genomic regions called polycomb 
responsive elements (PREs) (Liu et al., 2015). EZH2 also methylates non-histone 
proteins such as STAT3, GATA4, RORα, resulting in their regulation (Figure 9) (He et 
al., 2012; E. Kim et al., 2013; Lee et al., 2012). Interestingly, apart from its 
transcriptional repressive function, in certain context, EZH2 can also display trans-
activating functions positively influencing NF-κB, Wnt/ β-catenin and ERα-driven 
signaling, in a PRC2-indendependent manner (Jung, H. et al., 2013; K. H. Kim & 
Roberts, 2016). EZH2 can cooperate with the androgen receptor (AR) and the 
estrogen receptor (ERα), promoting prostate and breast cancer progression, 






Figure 9:  EZH2 transcriptional activity. PRC2/EZH2 gene silencing via H3K27me3, EZH2 methylation 
of non-histone proteins and PRC2-independent EZH2 transcriptional activation (modified from K. H. 
Kim & Roberts, 2016). 
 
Aberrant PRC2/EZH2 activity is known to have oncogenic activity in a number of 
tumors (C. Chang & Hung, 2011). EZH2 is very frequently overexpressed in diverse 
tumors entities like pancreatic, prostate, breast and bladder cancer (Y. Chen et al., 
2010; Kleer et al., 2003; Raman et al., 2005; Varambally et al., 2002). A few studies 
suggest a pro-tumorigenic EZH2 activity in TNBC. Chien et al. suggest that EZH2 
promotes TNBC invasiveness via TIMP2/MMP-2 and -9 regulation (Chien et al., 2018) 
Another study on MDA-MB-231, a TNBC cell line, revealed that co-treatment with 
EZH2 and HDAC inhibitors leads to tumor cell death.  
However, a growing number of studies reported an anti-tumorigenic function of 
PRC2/EZH2. In medulloblastoma, it was shown that the inactivation of EZH2 can 
promotes Myc-driven cancer (Vo et al., 2017). It was also reported that PRC2 loss 
promotes chemoresistance with reduction of apoptosis in T cell acute lymphoblastic 
leukemia (Ariës et al., 2018). The role of EZH2 remains elusive in distinct TNBC 
subgroups. EZH2 could be an oncogene or tumor suppressor in TNBC and can 





H3K27 can be methylated as mentioned before but also acetylated through 
histone acetyltransferases (HATs) transfer an acetyl group from a donor molecule, 
acetyl coenzyme A (acetyl-CoA), to the ɛ-amino group of lysine residues of the 
substrate (Vogelauer et al., 2012). Histone acetylation can be reversed by histone 
deacetylases (HDACs). HDACs can be classified into class I (HDAC1, -2, -3, -8) class 
IIa (HDAC4, -5, -7, -9), class IIb (HDAC6, -10), class III (sirtuins) and class IV 
(HDAC11) (Gregoretti et al., 2004). 
Aberrant HDAC gene expression is frequently associated with cancer 
development (reviewed in Y. Li & Seto, 2016). HDACs are overexpressed in various 
tumors including gastric, breast and prostate cancer, which have higher levels of 
HDAC1 and colorectal cancer, which upregulate HDAC2 and HDAC3 (Kawai et al., 
2003; Mariadason, 2008; Weichert et al., 2008). HDAC inhibitors (HDACi) represent 
interesting molecules to reverse cancer progression, as they can change the 
acetylation status of histone and non-histone proteins (Figure 10). HDAC inhibition 
can alter gene expression inducing apoptosis through Fas, DR5, TRAIL and caspases 
(Rosato, 2005). These inhibitors have also been shown to impose cell cycle arrest at 
G0/G1 or G2/M checkpoints and to reduce angiogenesis and metastasis. HDACs are 
able to target cytoplasmic proteins, such as heat shock protein 90 (HSP90), DNA 
repair factor Ku70, α-tubulin and β-catenin (Krämer et al., 2014; Ma et al., 2009). 
Additionally, it was shown that inhibition of HDACs can suppress TGF-β1-induced 





Figure 10: Cellular effects of HDAC inhibitors in cancer. Inhibition of chromatin repression via HDACi 
can affect apoptotic, cell cycle, angiogenic and metastatic changes in cancer cells through abrogation 
of acetylation/ deacetylation balance in chromatin and non-histone proteins (modified from Ma et al., 
2009) 
 
One of the most well-known and FDA approved drugs in T-cell lymphoma are 
Vorinostat (SAHA) and Panobinostat (LBH589) which are pan-HDAC inhibitors, 
targeting class I and II HDACs (Marks & Breslow, 2007; Ververis et al., 2013). In 
breast cancer, HDAC inhibitors can be used as monotherapy or in combination with 
other drugs, such as lapatinib (anti-HER2), tamoxifen (anti-ER), olaparib (PARPi) or 
cisplatin (Hasan et al., 2018; Min et al., 2015; Solomon et al., 2015). 
Despite many promising in vitro and in vivo studies, results from preclinical 
trials failed when HDACi was used as a single agent (Slingerland et al., 2014). HDAC 
inhibitors have shown promising results in combination with other anticancer 
therapies. According to studies on MDA-MB-231, a TNBC cell line, SAHA treatment  
alone promotes EMT transition via HDAC8/FOXA1 signaling (Oehme et al., 2009). 
Instead, SAHA in combination with IR radiation or cisplatin can decrease tumor 
growth, induce apoptosis and cell cycle arrest (Chiu et al., 2013). Furthermore, the 
18 
 
use of a combination of DNA methyltransferases (DNMT) and HDAC inhibitors to 
dampen TNBC aggressiveness was proposed recently (Su et al., 2018).  
1.4. NFAT family 
 The Nuclear factor of activated T cells (NFAT) family is composed of 
transcription factors, which induce gene expression during immune responses (Rao 
et al., 1997). The first report on NFATc2 described it as a DNA-binding protein binding  
to the interleukin-2 (IL-2) promoter in T cells (Shaw et al., 1988). It is known that 
NFATs exist also in other immunoregulatory cells such as B cells, NK cells, 
macrophages, etc. (Rao et al., 1997). Recently, particular research efforts have been 
made to unravel the function of NFATs factors in cancer (Robbs et al., 2008).     
1.4.1. NFAT proteins 
The NFAT family consists of five members: NFAT1 (NFATc2), NFAT2 (Nfatc1), 
NFAT3 (NFATc4), NFAT4 (NFATc3) and NFAT5 (Rao et al., 1997) (Table I 1). 
NFAT1-4 have a regulatory region called NFAT homology region (NHR) including the 
transactivation domain (TAD) and a calcineurin docking site (CDS). Moreover, there 
is a highly conserved DNA-binding domain called Rel-homology domain (RHD) and a 
carboxy-terminal domain (Luo et al., 1996; Müller & Rao, 2010). Within conserved 
serine-rich regions (SRR), there are 14 docking sites for phosphorylation of NFATs by 
CK1, GSK3 and DYRK (Hogan et al., 2003). The N-terminal domain contains two 
nuclear localization sequences (NLS1, NLS2) and one nucleus export signal (NES) 
controlling subcellular transport and localization (Beals et al., 1997).   
1.4.2. NFAT activation 
Except for NFAT5 that is activated by osmotic stress, NFAT1-4 are calcium 
responsive proteins. (Luo et al., 1996). NFATs become activated after cytosolic Ca2+ 
influx, which is a consequence of G protein coupled receptor signaling or ER stress 
(Prakriya et al., 2006). Upon physiological stimulation and decrease of Ca2+ levels in 
the ER, the plasma membrane-located CRAC channel is activated to restore calcium 
ions to normal levels, thus increasing cytosolic calcium levels. Cytoplasmic calcium 
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binds to and induces conformational changes of the protein calmodulin. The latter can 
then bind and activate calcineurin, a calcium-dependent phosphatase that is able to 
dephosphorylate NFATs, rendering them active. The phosphorylation status of NFATs 
determines their activity and intracellular localization where highly phosphorylated 
NFATs remain in the cytoplasm and calcineurin-dependent dephosphorylated NFATs 
are translocated to the nucleus (Hogan et al., 2003).  
 
Table 1.  NFATc1 family members and their regulation (adapted from Macian, 2005). 
 
 
The NFAT signaling pathway is reported to be related to cancer progression 
(Mancini & Toker, 2009). The calcineurin inhibitor, cyclosporine A (CsA) can reduce 
NFAT activity by binding to cyclophlin A and creating a complex that prevents 
calcineurin from interacting with calmodulin even in the presence of calcium (Flanagan 
et al., 1991). Studies demonstrate that cyclosporine A is well tolerated by patients in 
advanced solid malignancies in I/IB clinical trials. They present CsA as calcineurin 
inhibitor suppressing Wnt/Ca2+/NFAT pathway (Krishnamurthy et al., 2018). CsA 
could also be combined with chemotherapy treatment of drug-resistant solid tumors 
(Stiff & Marrow, 1995). Another, more selective NFAT inhibitor is VIVIT and its 
therapeutic potential was observed in cardiovascular disorders and chronic 
lymphocytic leukemia resulting in the reduction of disease progression (Le Roy et al., 
2012; Yu et al., 2007).  The catalytic inhibition of sarcoplasmic reticulum ATPase 
(SERCA2) by thapsigargin makes it possible to investigate the role of NFATs in vitro 






Figure 11: NFAT activation. Calcium/calcineurin, in the presence of Ca2+ ions, can dephosphorylate 
NFATs resulting in their translocation to the nucleus. CsA and Thapsigargin inhibit and activate NFATs, 
respectively (modified from Vaeth & Feske, 2018).  
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1.5. Aims of the study 
Triple-negative breast cancer (TNBC) is the most challenging breast cancer 
subtype in the clinic routine. Due to lack of hormone therapy, conventional 
chemotherapy remains the mainstay in TNBC treatment. However, some cancer cells 
can be insusceptible to cytotoxic drugs leading to cancer recurrence. Remaining tumor 
cells adapt to hostile conditions by changing their gene expression and phenotype. 
Shedding light on the mechanisms driving chemotherapy-resistance is of utmost 
importance to understand TNBC progression.  
            Epigenetic regulatory pathways are fast and therefore likely to be implicated in 
overcoming chemotherapy that is to be associated with switches in gene expression 
pattern and acquisition of more aggressive features. The initial aim of this study was 
therefore to identify altered epigenetic mechanisms upon survival of tumor cells to 
cytotoxic drugs. Genome wide transcriptome (mRNA-seq) and histone mark occupancy 
(ChIP-seq) analyses were designed to identify up- or down-regulated epigenetic factors 
and to unravel the potential gene expression programs under control of these 
epigenetic processes. After subsequent validation of the findings via IHC staining on 
tumor material and via publically available databases mining, we aimed to assess the 
potential of interfering with the newly identified epigenetic mechanisms of survival to 
chemotherapy via in vitro functional assays.  
Taken together, the present study ultimately aimed to provide new insights about 
mechanisms underlying chemotherapy resistance that could subsequently serve as a 





2100 Bioanalyzer     Agilent Technology, Santa Clara, USA 
Agarose gel chamber  Harnischmacher Labortechnik, Kassel, 
Germany 
Balance 440-35N    Kern & Sohn GmbH, Balingen, Germany 
Biological Safety Cabinet “Safe 2020”    Thermo Fisher Scientific, Waltham, USA 
Celigo® S Cell Imaging CytometerNexcelom Bioscience LLC, Lawrence, USA 
Centrifuge (Megafuge 1.OR)   Thermo Fisher Scientific, Waltham, USA 
Centrifuge (5417R)     Eppendorf, Hamburg, Germany 
Centrifuge (Heraeus Fresco 21)   Thermo Fisher Scientific, Waltham, USA 
Counting chamber (Neubauer)   Brand GmbH & Co. KG, Wertheim, Germany 
DynaMag-2      LifeTechnology, Carlsbad, USA 
DynaMag-96 Side Magnet   LifeTechnology, Carlsbad, USA 
Eclipse TS100     Nikon, Tokio, Japan 
Electrophoresis & Electrotransfer Unit    GE Healthcare Europe GmbH, München,       
      Germany 
Freezer -150 °C (MDF-C2156VAN)  Panasonic, Kadoma, Japan 
Freezer -20 °C    Liebherr GmbH, Biberach, Germany 
Freezer -80 °C “Hera freeze”   Thermo Fisher Scientific, Waltham, USA 
Gel iX Imager  Intas Science Imaging GmbH, Göttingen, 
Germany 
HERAcell 150i CO2 Incubator   Thermo Fisher Scientific, Waltham, USA 
Imager Western Blot    Bio-Rad Laboratories, Hercules, USA 
Inverse Microscope “Axiovert 40 CFL”   Carl Zeiss MicroImaging GmbH, Göttingen, 
Germany 
Isotemp® water bath    Thermo Fisher Scientific, Waltham, USA 
Magnet stirrer “MR3001”  Heidolph GmbH & Co. KG, Schwabach, 
Germany 
Microcentrifuge C1413-VWR230   VWR, Radnor, USA
Microscope Axio Scope.A1 with             Carl Zeiss MicroImaging GmbH, Göttingen, 
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an AxioCam MRc                                     Germany
Microscope Axiovert 100  Carl Zeiss MicroImaging GmbH, Göttingen, 
Germany 
Microwave  Clatronic International GmbH, Kempen, 
Germany 
Mini Trans-BlotTM Cell    Bio-Rad Laboratories, Hercules, USA 
Mini-PROTEAN Tetra Cell    Bio-Rad Laboratories, Hercules, USA 
Mr. Frosty® Cryo Freezing Container      Thermo Fisher Scientific, Waltham, USA 
Nano Drop® ND-1000  Peqlab Biotechnology GmbH, Erlangen, 
Germany 
Optical Reaction Module CFX96TM      Bio-Rad Laboratories, Hercules, USA 
pH meter inoLab®     WTW GmbH, Weilheim, Germany 
Pipette Aid® portable XP    Drummond Scientific Co., Broomall, USA 
Pipettes “Research” Series   Eppendorf, Hamburg, Germany  
Power supply Power Pack P25T   Biometra GmbH, Göttingen, Germany 
PowerPacTM Basic Power Supply     Bio-Rad Laboratories, Hercules, USA 
PowerPacTM HC Power Supply             Bio-Rad Laboratories, Hercules, USA 
Qubit® 2.0 Fluorometer    Invitrogen GmbH, Karlsruhe, Germany 
Photo Scanner Epson V700   Seiko Epson, Suwa, Japan 
Refrigerator      Liebherr GmbH, Biberach, Germany 
Shaker “Rocky”  Schütt Labortechnik GmbH, Göttingen, 
Germany 
Test Tube Rotator  Schütt Labortechnik GmbH, Göttingen, 
Germany 
Thermal Cycler T100TM    Bio-Rad Laboratories, Hercules, USA 
ThermoMixer C     Eppendorf, Wessling-Berzdorf, Germany 




2.2. Consumable materials 
 
96-well Multiplate® PCR plate, white  Bio-Rad Laboratories, Hercules, USA 
Cell scraper (16 cm, 25 cm)   Sarstedt AG & Co., Nümbrecht, Germany 
Cell culture dishes (10 cm, 14.5 cm) Greiner Bio-One GmbH, Frickenhausen,  
                                                                 Germany 
Cellstar 6-,12-well cell culture plates   Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Costar 24- well cell culture plates Corning Incorporated, New York, USA 
 
2.3. Chemicals and kits 
2.3.1 Reagents 
Acetic acid  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Agarose      GeneOn GmbH, Ludwigshafen, Germany 
Albumin Fraction V (BSA)   Carl Roth GmbH & Co. KG, Karlsruhe,                                                   
 Germany                                                                   
Ammonium persulfate (APS)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Ammonium sulfate (NH4)2SO4 Carl Roth GmbH & Co. KG, Karlsruhe,         
Germany 
Aprotinin  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Bromophenol blue     Sigma-Aldrich Co., St. Louis, USA 
Calcium Chloride (CaCl2)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Colorless co-precipitant    Ambion, Altham, USA 
Co-precipitant Pink     Bioline, Luckenwalde, Germany 
Crystal violet     Merck Millipore, Darmstadt, Germany 
Cyclophosphamide     Pharmacy, University Medicine Göttingen 
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Cyclosporine A     Biozol, Eching, Germany 
Diethylpyrocarbonate (DEPC)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Dimethyl sulfoxide (DMSO)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
di-Sodium hydrogen phosphate  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
DMEM  GlutaMax GIBCO, Invitrogen GmbH, 
Darmstadt, Germany 
dNTPs      Jena Bioscience GmbH, Jena, Germany 
Doxorubicin      Pharmacy, University Medicine Göttingen 
Ethanol absolute     Merck Millipore, Darmstadt, Germany 
EDTA  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
EPZ-6438 (S7128)     Selleckchem, Houston, USA 
Fetal Bovine Serum (FBS)   Thermo Scientific HyClone, Logan, USA 
Fluorouracil      Pharmacy, University Medicine Göttingen 
Formaldehyde     Sigma-Aldrich Co., St. Louis, USA 
Gene RulerTM DNA-Ladder   Fermentas GmbH, St. Leon-Rot, Germany 
Glycerol  Carl Roth GmbH & Co. KG, 
Karlsruhe,Germany 
Glycine Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Guava EasyCyte plus   Guava Technologies Inc., San Francisco, 
USA 
HD Green® DNA stain  Intas Science Imaging GmbH, Göttingen, 
Germany 
Hydrochloric acid (HCl)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Iodacetamide     Sigma-Aldrich Co., St. Louis, USA 
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Isopropanol  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Leupeptin  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Lithium chloride (LiCl), 8M    Sigma-Aldrich Co., St. Louis, USA 
Magnesium chloride (MgCl2)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Methanol  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
N-ethylmaleimide (NEM)    Sigma-Aldrich Co., St. Louis, USA 
Nickel chloride (NiCl2)    Sigma-Aldrich Co., St. Louis, USA 
N-Lauryl sarcosine     Sigma-Aldrich Co., St. Louis, USA 
NonidetTM P40 (NP-40)    Sigma-Aldrich Co., St. Louis, USA 
Opti-MEM  GIBCO Invitrogen GmbH, Darmstadt, 
Germany 
PageRulerTM Prestained Protein Ladder Fermentas GmbH, St. Leon-Rot , Germany 
PBS tablets GIBCO Invitrogen GmbH, Darmstadt 
Germany 
Pefabloc SC Protease Inhibitor  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Penicillin-Streptomycin solution   Sigma-Aldrich Co., St. Louis, USA 
PMSF  Calbiochem, VWR International GmbH, 
Darmstadt, Germany 
Proteinase K     Invitrogen GmbH, Karlsruhe , Germany 
Protein-A Sepharose    CL-4B GE Healthcare, Uppsala, Sweden 
Reverse Transcriptase (M-MuLV)  New England Biolabs, Frankfurt am Main, 
Germany 
Roti Phenol/Chloroform/ Isoamyl   Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 




Rotiphorese Gel 30  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Rotipuran Chloroform  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
RPMI 1640      Life Technologies, Carlsbad, USA 
SepharoseTM CL-4B    GE Healthcare, Uppsala, Sweden 
Skim milk powder  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium acetate  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium azide     AppliChem GmbH, Darmstadt, Germany 
Sodium chloride (NaCl)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium deoxycholate    AppliChem GmbH, Darmstadt, Germany 
Sodium dodecylsulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Sodium fluoride (NaF)    AppliChem GmbH, Darmstadt, Germany 
Sodium hydroxide (NaOH)  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
β-Glycerolphosphate (BGP)   Sigma-Aldrich Co., St. Louis, USA 
SYBR Green  Roche Diagnostics GmbH, Mannheim, 
Germany 
Taq DNA Polymerase    Prime Tech, Minsk, Belarus 
TEMED  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
TMP195 Biomol, Hamburg, Germany 
TMP269 Biomol, Hamburg, Germany 
Tris  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
Triton X-100      AppliChem GmbH, Darmstadt, Germany 
TRIzol Reagent     Invitrogen GmbH, Karlsruhe, Germany 
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Trypsin-EDTA (0.05%)  GIBCO, Invitrogen GmbH, Darmstadt, 
Germany 
Tween-20  Carl Roth GmbH & Co. KG, Karlsruhe, 
Germany 
α,α-Trehalose Dihydrate    AppliChem GmbH, Darmstadt, Germany 
 
2.3.2 Kits 
Bioanalyzer DNA High sensitivity kit  Agilent Technologies, Santa Clara, USA 
Immobilon Western HRP Substrate Millipore, Billerica, USA 
innuPREP RNA Mini Kit 2.0  Analytik Jena AG, Jena, Germany 
KAPA Hyper Prep kit Roche, Pleasanton, USA 
NEXTflex™ Rapid Illumina Directional                                                                          
RNA-Seq Library Prep Kit    Bio Scientific Corporation, Austin, USA 
Qubit dsDNA HS assay    Invitrogen GmbH, Karlsruhe, Germany 
Bioanalyzer DNA High sensitivity kit  Agilent Technologies, Santa Clara, USA 
SuperSignal™ West Femto Maximum                                                                        
Sensitivity Substrate   Thermo Fisher Scientific, Waltham, USA 
2.4. Nucleic acids 
2.4.1. RT-PCR primers 
 




GAGTCTACACGCTAGGCGTAA F. Wegwitz 
CTCGTGGCTAGTACCTCACTG F. Wegwitz 
E-cadherin 
CCTGGCACTGGTATCTCTTCA E. Lenfert 




Evx1_ChIP TGGCAGCAGCCTTAAACCTT This study 
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AGCTGCAGTAGACCGTTGAC This study 
Ezh2 
TCCATGCAACACCCAACACA W. Xie 
AACTCCTTAGCTCCCTCCAGAT W. Xie 
Hdac4 
CTGTGGAGCTGCTGAATCCT This study 
TTCCAAGGGCAGTGAGAACT This study 
Hdac7 
TCTCTTCCTGGCAGGCTTAC This study 
AGTTGCCGAAGTTCTTGCTC This study 
Hdac8 
ATGACTGTGTCCCTGCACAA This study 
CTGAATGGGCACATTGACAC This study 
N-cadherin 
GCGCAGTCTTACCGAAGGATG This study 
ATACACCGTGCCGTCCTCGT This study 
Nfatc1 
GCCTTTTGCGAGCAGTATCT E. Hessmann 
GCTGCCTTCCGTCTCATAGT E. Hessmann 
Nfatc2 
GAACAACATGAGAGCCACCA This study 
GTGTTCTTCCTGCCGATGTC This study 
Rplp0 
GATTCGGGATATGCTGTTGG This study 
GCCTGGAAGAAGGAGGTCTT This study 
Snai1 
CTGGTGAGAAGCCATTCTCCT E. Lenfert 
CCTGGCACTGGTATCTCTTCA E. Lenfert 
Suz12 
AGCATCAAAAGCTTGTCTGCAC W. Xie 








CACCAGAAGCCAGCAGTCAT This study 
CGTTCTTCTCATGGCGGTACT This study 
 
2.4.2 siRNAs for transient gene silencing 
 






EZH2 GAGGACGGCUUCCCAAUAA             
GCUGAAGCCUCAAUGUUUA          
UAACGGUGAUCACAGGAUA          
GCAAAUUCUCGGUGUCAAA 






















NFATc1  40657 Thermo Fisher  











Proteinase-K     Life Technology, Carlsbad, USA  
Reverse Transcriptase (M-MuLV)  New England Biolabs, FFM  
RNase A      Qiagen GmbH, Hilden  
RNase Inhibitor     New England Biolabs, FFM  
Taq DNA Polymerase    Prime Tech, Minsk, Belarus 
 
2.5.2. Antibodies 
Antibodies were diluted as mentioned below in 5% milk or BSA. Primary antibodies 








IHC IF ChIP FACS 
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Actin 8224 Abcam 1:2000     
E-cadherin 24E10 Cell 
Signaling 
1:1000     
Ezh2 5246/ D2C9 Cell 
Signalling 
1:1000 1:150 1:100   
FITC-α-
EpCAM 
118207 Biolegend     1:400 
H3 601902 Biolegend 1:500     
H3K27ac C15410196 Diagenode    2 μg 2 μg 
H3K27me3 C15410195 Diagenode    2 μg 2 μg 
N-cadherin D4R1H  1:1000     
Nfatc1 649601 Biolegend 1:500 1:25    
Suz12 D39F6/ 3737 Cell 
Signalling 
1:1000  1:100   
Vimentin 18814 Cell 
Signaling 








goat anti-mouse (IgG)HRP Sc-
2004 
Santa Cruz 1:10000  
goat anti-rabbit (IgG)HRP Sc-
2005 
Santa Cruz 1:10000  
donkey anti-goat (IgG)HRP Sc-
2020 
Santa Cruz 1:10000  
Alexa Fluor® 488 Goat Anti-
Rabbit IgG 
A11008 Life Technologies  1:10000 
Alexa Fluor® 555 Donkey Anti-
Mouse IgG 
A31570 Life Technologies  1:10000 
 
2.6. Cell culture 
2.6.1. Cell lines 
 
Cell line Medium Source 
pG-2 DMEM, GlutaMAX F. Wegwitz (AG Wegwitz), Göttingen 
rG-2 DMEM, GlutaMAX G. Schmidt (AG Wegwitz), Göttingen 
MDA-MB-468 RPMI-1640 ATCC® HTB-132 
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MDA-MB-231 RPMI-1640 ATCC® HTB-26 
HCC1806 RPMI-1640 ATCC® CRL-2335 
HCC70 RPMI-1640 ATCC® CRL-2315 
HCC1937 RPMI-1640 ATCC® CRL-2336 
 
2.6.2. Media and reagents 




Dulbecco’s Modified Eagle Medium 
(DMEM), high glucose, GutaMAX™ 
Gibco®, Invitrogen GmbH, Karlsruhe 
RPMI-1640 Gibco®, Invitrogen GmbH, Karlsruhe 
Fetal Bovine Serum (FBS) Thermo Scientific HyClone, Logan, 
USA 
Penicillin/streptomycin (P/S) Sigma-Aldrich Co., St. Louis, USA 
0.05% Trypsin-EDTA Gibco®, Invitrogen GmbH, Karlsruhe 




qPCR buffer Tris/HCl, pH 8.8 75 mM 
(NH4)2SO4 20 mM 
Tween 20 0.01% 
MgCl2 3 mM 
dNTPs 0.2 mM 
Triton X-100 0.25% 
Taq polymerase 20 U/ml 
SYBR Green I 1:80 000 
Trehalose 300 mM 
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Blocking solution Milk powder 5% (w/v) 
in TBS-T 1x  
CAF stock solution (1) 5-Fluorouracil  77 µM 
Doxorubicin 0.92 µM 
Cyclophosphamide 38 µM 
in cell culture medium  
ChIP wash buffer SDS 0.01% (w/v) 
Triton X-100 1.1% (v/v) 
EDTA 1.2 mM 
Tris-HCl, pH 8.1 16.7 mM 
NaCl 167 mM 
Citric acid buffer, pH 6.0 Citric acid 12 mM 
Tri-sodium citrate  100 mM 
Cross-linking buffer Formaldehyde in PBS 37% 
Crystal violet solution Crystal violet 0.1% (w/v) 
EtOH 20% 
DNA loading dye (6x) Sucrose 40% (w/v) 
Glycerol 10% (v/v) 
Bromophenol blue 0.25% (w/v) 
FACS resuspension buffer FBS 2% (v/v) 
EDTA in PBS 1 mM 
IP buffer NaCl 5 M 
EDTA, pH 8.0 0.5 M 
Tris-HCl, pH 8.0 1 M 
NP-40 10% (v/v) 
Sodium deoxycholate 10% (w/v) 
NaF 0.5 M 
SDS 10 % (w/v) 
Lämmli buffer (6x) DTT 9.3% (w/v) 
Tris, pH 6.8 0.35 M 
Glycerol 30% (v/v) 
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SDS 10% (w/v) 
Bromophenol blue 0.02% (w/v) 
Nuclear preparation buffer NaCl 5 M 
EDTA (pH 8.0) 0.5 M 
Tris-HCl (pH 7.5) 1M 
NP-40  10% (v/v) 
Triton-X-100 (v/v) 10% (v/v) 
NaF 0.5 M 
PBS for cell culture PBS tablet 1x 
ddH2O 500 ml 
PBS, pH 7.4 NaCl 137 mM 
Na2HPO4.2H2O 4.29 mM 
KCl 2.68 mM 
KH2PO4 1.47 mM 
PBS-T Tween-20 in PBS 0.1% (w/v) 
RIPA buffer NP-40 1% 
SDS 0.1% 
Sodium deoxycholate in PBS 0.5% 
RNA loading dye Bromophenol blue 0.1% (w/v) 
DEPC water 49.9% 
Glycerol 50% (w/v) 
Running buffer  Glycine 200 mM 
Tris 25 mM 
SDS (w/v) 0.1 % 
SDS-PAGE running buffer Tris 25 mM 
Glycerine 86 mM 
SDS 3.5 mM 
SDS-PAGE separating gel Acrylamide 33% (v/v) 
APS 0.1% (w/v) 
SDS 0.1% (w/v) 
Tris/HCl, pH 8.8 375 mM 
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TEMED 0.04% (v/v) 
SDS stacking gel Acrylamide 33% (v/v) 
APS 0.1% (w/v) 
SDS 0.1% (w/v) 
Tris/HCl, ph 6.8 125 mM 
TEMED 0.01% (v/v) 
TAE (50x) buffer Tris 2 M 
Acetic acid 1 M 
EDTA 0.1 M 
TBE buffer Tris 45 mM 
Na2EDTA 1 mM 
Boric acid 45 mM 
TBS, pH 7.4 NaCl 150 mM 
KCl 2.68 mM 
Na2HPO4×2H2O 4.29 mM 
KH2PO4 1.47 mM 
TBS-T Tween-20 in TBS 0.1% (w/v 
TE buffer EDTA, pH 8.0 0.5 M 
 Tris-HCl, pH 8.0 1 M 
Transfer buffer 10x western salts 10% (v/v) 
Methanol 20% (v/v) 
Western salts (10x), pH 8.3 Glycine 1.92 M 
SDS 0.02% (w/v) 
Tris/HCl 250 mM 
 
2.8 Softwares and online tools 
Bio-Rad CFX Manager  Bio-Rad Laboratories, Hercules, USA 




DiffBind package   http://bioconductor.org/packages/release/bioc/ 
 html/DiffBind.html 
Enrichr  https://amp.pharm.mssm.edu/Enrichr/ 
Galaxy Deeptools   http://deeptools.ie-freiburg.mpg.de/ 
Gene Set Enrichment Analysis  http://software.broadinstitute.org/gsea/index.jsp 
GIMP 2.10.6  https://www.gimp.org/ 
GraphPad Prism   https://www.graphpad.com/scientific-   
software/prism/ 
GREAT analysis software  http://bejerano.stanford.edu/great/public/html/ 
Image Lab Version 5.2   Bio-Rad Laboratories, Hercules, USA 
Kaplan-Meier plotter  http://kmplot.com/analysis/index.php?p  
=background 
MERAV http://merav.wi.mit.edu/ 
NCBI primer-BLAST   www.ncbi.nlm.nih.gov/tools/primer-
blast/Primer/designing tool/                                                                                                       
R Studio 3.5    https://www.rstudio.com/products/rstudio/ 
useGalaxy    https://usegalaxy.org/ 




3.1. Cell culture 
3.1.1. Cell maintenance 
pG-2 and rG-2 cells were cultured in DMEM GlutaMAX, whereas MDA-MB-468, MDA-
MB-231, HCC1937, HCC1806, HCC70 were maintained in RPMI-1640 at 37°C and 5% 
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CO2. All media were supplemented with 10% FBS, 100 U/ml penicillin, 100 μg/ml 
streptomycin. For cell passaging 1x PBS and 0.05% Trypsin-EDTA were used. 
 
3.1.2. Reverse transfection 
Cells were reverse transfected with siRNA in 6-well plates using Lipofectamine® 
RNAiMAX, according to the manufacturer’s instructions. 1.5 µl of 20 µM siRNA was 
mixed gently with 5 µl Lipofectamine® RNAiMAX and 500 µl of Opti-MEM and incubated 
for 20 minutes at room temperature. After transferring 500 µl of the prepared 
transfection mixture to the well, 1.5 ml of Opti-MEM with 350,000 cells were added and 
the plate was kept in the incubator in normal cell culture conditions. After 24 hours, the 
cells were used for other assays. 
3.1.3. Cell proliferation assay 
24-well plates with seeded 10.000 cells per well were used to assess cell proliferation. 
If the cells were already transfected with siRNA, after 48 hours cells were treated with 
chemotherapy. In the case of inhibition, cells were treated with inhibitor the day after 
seeding and incubated for 48 hours, for the next 2 days inhibition and chemotherapy 
treatment was performed or inhibition alone. For the next 48 hours, cells were treated 
again with inhibitor and afterwards with fresh medium only. Every 2 days cells 
proliferation was measured using the Celigo® Adherent Cell Cytometer for a total of 1- 
2 weeks, depending on the treatment and the cell line. On the last day of the 
experiment, the cells were fixed with 100% methanol and stained using 0.1% crystal 
violet in EtOH.  
 
3.1.4. Migration assay 
Scratch assay. 400.000 cells, previously transfected with siRNA or treated with 
inhibitor, were seeded on each well. The next day, if the cells were 95% confluent, 
scratches on monolayer of cells were performed using pipette tips. Immediately, 
medium was changed for fresh medium with no FBS. Photos were taken after 0 and 12 
hours and analyzed via ImageJ.  
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Boyden chamber assay. Boyden chamber inserts (8.0-µl track-etched membrane cell 
culture inserts) were equilibrated with serum free medium supplemented with penicillin 
and streptomycin. Inserts were transferred into 24-well plates containing 500 µl a 
complete cell culture medium. 50.000 cells in 300 µl serum free medium were seeded 
into the inserts. After 48 hours, the inserts were washed with PBS and cells on the 
upper site of the insert were carefully removed. Cells on the lower side of the insert 
were fixed using 4% PFA for 10 min and stained with 1% crystal violet in 20% EtOH for 
20 min. After drying, photos were taken and analyzed using ImageJ. 
 
3.1.5 Colony formation assay 
2.000 cells after siRNA transfection or subsequent treatments were seeded per well in 
a 6-well plate. The colonies were stained with crystal violet and counted manually at 
the end of the experiment.   
 
3.2. Molecular biology 
3.2.1. RNA isolation 
From a 6-well plate, the cells were washed with PBS and resuspended in 500 µl of 
TRIzol®. According to manufacturer’s manual, 200 µl chloroform was added and 
vortexed for 15 seconds. After centrifuging at 4°C, 12.000 g for 15 min, the aqueous 
phase was taken and vigorously mixed with an equal volume of isopropanol. After 
minimum 1 hour of precipitation at -80°C, the samples were centrifuged at 4°C, 12,000 
g for 15 min. The RNA pellets were washed 2x with cold 70% ethanol in DEPC water. 
Finally, the supernatant was discarded completely and the RNA pellets were air dried 
for around 10 minutes and diluted in 40 µl DEPC water. The RNA quantification was 
performed using the Spectrophotometer, Denovox. Alternatively, the innuPREP RNA 
Mini Kit 2.0 from Analytik Jena AG was used for RNA isolation and the manufacturer’s 




3.2.2. cDNA synthesis 
 
For the cDNA synthesis, a mixture of 0.5-1 µg of RNA, 2 µl 60 µM random primers, 1 
µM dNTPs and DEPC water in a total volume of 10 µl was prepared and incubated at 
65°C for 5 min and cooled down on ice. 2 µl 10 x M-MuLV buffer, 0.25 µl [10 U] RNase 
inhibitor, 1 µl M-MuLV reverse transcriptase and DEPC in a volume of 10 µl were added 
to each reaction mix. The samples were incubated at 25°C for 5 min, 42°C for 1 h and 
95°C for 5 min. The cDNA samples were diluted to 5ng/µl and stored at -20°C or -80°C. 
3.2.3. Quantitative real-time PCR 
To quantify relative gene expression, 1 µl of cDNA was used in master mix containing 
14 µl 2x qPCR mix, 9 µl ddH2O and 1 µl primers in one reaction. Firstly, the cDNA was 
denatured at 95°C for 2 min, then 40 cycles of 95°C for 15 s and 60°C for 30 sec were 
run. Finally, the melting curve analysis was generated with SYBR green by heating 
from 60°C to 95°C with one read every 0.5°C. Based on the standard curve, the results 
were quantified. 
3.2.4.1. Crosslinking 
For ChIP, pG2 cells cultured with or without chemotherapy treatment for 48 hours on 
15 cm plates were used. The cells were crosslinked with 1% formaldehyde in PBS for 
20 min, followed by quenching with 125 mM glycine for 5 min. After washing the cells 
2x with cold PBS, 1 ml of nuclear preparation buffer containing a proteinase inhibitor 
cocktail was added. Scraped cells were centrifuged at 12.000 g for 2 min at 4 °C and 
the nuclear pellet was washed with nuclear preparation buffer.  
3.2.4.2. DNA content determination  
50µl of the supernatant was transferred from the crosslinking step prior to the last 
centrifugation. After adding 250µl of sonication buffer-1 and 1µl of Proteinase K (20 
mg/ml), the samples were incubated at 65°C overnight, 800 rpm. 250µl of distilled 
water, 25µl of 8M LiCl and 2µl of colorless co-precipitant were added to each tube. 
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Upon phenol/chloroform/isoamylic alcohol extraction, samples were vortexed and 
centrifuged 12,000 g, 2 min, 4°C and the aqueous phase was transferred to a fresh 
tube. To precipitate, 1 ml of isopropanol was added to each sample, which was then 
incubated for 1h at -80°C. After 30min of centrifugation at 15.000 g, 4°C, the pellet was 
washed 2x with 70% EtOH. Afterwards, the final pellets were resuspended in 50 µl Tris 
10mM pH 8 with RNase A 100 µg/ml and quantified with the spectrophotometer. 
3.2.4.3. Sonication 
Based on the DNA concentration, the samples were diluted to 500 µg/ml and incubated 
at 4°C for 15 min on the wheel. The samples were sonicated using the Bioruptor Pico 
for 5, 10, 15, 20, 25 and 30 cycles with 30 sec on/off duty time. After centrifuging at 
10.000 g, 10 min, 4°C, a fraction of the supernatants was taken for a shearing check. 
3.2.4.4. Shearing check 
100 µl of sonication buffer-1 and 1 µl of proteinase K were added to each sample, which 
were then incubated at 65°C for 4h, 800rpm. Next, 100 µl water, 10 µl 8M LiCl and 2 µl 
PINK precipitant were added. Phenol/chloroform/isoamylic alcohol was added to each 
sample, followed by 30s vortexing and centrifuging at 2 min, 15 000 g. To the aqueous 
phase, 1 ml EtOH was added and after 1h of incubation at -80°C, the samples were 
centrifuged for 30 min, 15 000 g, 4°C. The final pellet was resuspended in 15 µl Tris 10 
mM pH 8.0 with RNase A 100 µg/ml (1h, 37°C, 700 g). The samples were mixed with 
3 µl of loading dye and run on a 1.5% agarose gel using 1x TAE buffer.  
3.2.4.5. Pre-clearing and chromatin immunoprecipitation 
For pre-clearing, 100 µl of a 50% sepharose slurry were added and the samples were 
incubated for 1h, 4°C. After centrifuging at 12 000 g, 4°C, the supernatant was collected 
and immunoprecipitation and input samples were prepared. Aliquots of chromatin were 
filled to 500 µl with IP buffer with protease inhibitors and appropriate antibodies (see: 
Materials) with overnight incubation. On the following day, 30 µl of protein A- sepharose 
was added and the samples were incubated for 2h at 4°C with rotation. The ChIP 
complexes washed with IP buffer, wash buffer and TE buffer.  
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3.2.4.6. DNA isolation 
Immunoprecipitated chromatin was treated with 50 µl of 10 µg RNase A diluted in Tris 
10 mM pH 8 for 30 min, at 37°C. 50 µl of sonication buffer was added on the beads 
with 1 µl proteinase K with overnight incubation at 65°C with shaking. After centrifuging 
(2.000 g, 2 min, at room temperature), the supernatant was taken and 10 µl Tris 10 mM 
pH 8 was added, mixed and centrifuged, 2 min 15.000 g. The aqueous phase was 
taken and to precipitate, 1 ml EtOH was used for 2h at -80°C. Next the samples were 
centrifuged for 30 min, 15.000 g, 4°C and washed with 1 ml 70% EtOH. The DNA was 
resuspended in 40 µl H20. 5 µl of each sample was used for ChIP-qPCR. 
 
3.2.4.7. ChIP-seq library preparations  
ChIP-seq libraries were prepared using the KAPA Hyper Prep kit according to 
manufacturer’s protocol. The libraries were purified using 1X AMPure® XP beads on a 
magnetic stand. The quality of the samples was determined using Bioanalyzer with 
assessment of the fragment length (around 300 bp). A 2 nM pool of ChIP DNA libraries 
were sequenced by the Transcriptome and Genome Analysis Laboratory in Göttingen 
(HiSeq 4000). 
3.2.4.8. ChIP-seq analysis 
 
For ChIP-seq analysis, the Galaxy server was used. ChIP-seq reads of two biological 
replicates for each condition in the experiment were used. FASTQ quality check 
(FastQC) of raw data was followed by Mapping, BamCoverage and Peak Calling. The 
sequenced reads were aligned to the mouse reference genome (mm9) using Bowtie2 
(http://bowtie-bio.sourceforge.net/bowtie2/index.shtml). Sequence Alignment Map 
(SAM) files  were converted to Binary Alignment Map (BAM) files using SAMtools (H. 
Li et al., 2009). After merging replicates (BAM files), Model-based Analysis of ChIP-seq 
2 (MACS2) was used for peak calling to identify enriched regions (Zhang et al., 2008). 
The next step was to generate a coverage file of the reads using bamCoverage with 
500bp bin size and reads per kilobase per million (RPKM) normalization. Through 
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conversion of BAM files to bigwig files, we could visualize ChIP-seq data. Further 
analysis was performed using computeMatrix, plotHeatmap and plotProfile. 
Additionally, differential binding analysis was performed for H3K27ac and H3K27me3 
binding sites using the R package DiffBind (Stark & Brown, 2011). Enrichr was 
performed based on significantly enriched genomic regions. 
3.3. Protein analysis 
3.3.1. Protein harvesting 
Cells were washed with PBS and scraped in ice-cold RIPA buffer with a protease 
inhibitors cocktail: 1 mM Pefabloc, 1 ng/µl Aprotinin/Leupeptin, 10 mM BGP, 1 mM NEM 
and 8M urea (1/3 of the final volume). The samples were sonicated for 10 cycles at 30 
sec on/off duty time using Biorupter Pico sonicator. After centrifugation for 10 min, 
12,000 g, 4°C, the protein samples were mixed with Lämmli buffer (Laemmli, 1970) and 
cooked for 5 min at 95°C. Protein samples with the same concentration, were 
separated using polyacrylamide gel during SDS-PAGE electrophoresis. Gels were run 
using running buffer at range of 70-120V.  
3.3.2. Western blot 
For an electrophoretic protein transfer (Towbin, 1979), nitrocellulose membranes were 
used. After the transfer, the membranes were blocked in 5% milk in TBS-T for 1h and 
incubated overnight in primary antibody at 4°C. Following, the membranes were 
washed with TBS-T and incubated for 1h in secondary antibody diluted. After washing 
the membranes 3 times washing in TBS-T for 5 minutes each, they were developed 
using HRP signal and the western blot imager Biorad. 
 
3.4. Stainings 
3.4.1. Crystal violet staining 
To analyze cell proliferation and colony formation, the cells were stained with 0.1% or 
1% crystal violet in 20% EtOH (modified from (Saotome, 1989)). The cells were washed 
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with PBS, fixed with 100% methanol for 5 min and stained with 0.1% crystal violet for 
20 min, room temperature. After drying, the plates were scanned and analyzed. 
 
3.4.2. IHC staining 
Tumor sections were deparaffinized after melting for 10 min at 48°C. Following, they 
were incubated in xylene for 20 min, xylene 1:1 with 100% EtOH, 100% isopropanol, 
EtOH 100%, 90%, 70% each for 5 min. After washing, the sections were cooked with 
EDTA or citric acid containing buffer for 10 min. Then, endogenous peroxidase was 
blocked with 3% superoxide in PBS for 45 min. The samples were washed in PBS and 
blocked with 3-5% BSA diluted in PBS for 1h, room temperature. Primary antibodies 
diluted in PBS were applied on top of the sections, overnight at 4°C. To proceed, 
washing and biotinylated secondary antibodies incubation was carried out. After 1h, 
sections were washed and treated with avidin 1:1000 in PBS with 90 min incubation 
and washing afterwards. Development was performed using DAV until strong signal 
appeared. The sections were counterstained with hematoxylin and eosin. Finally, the 
samples were incubated in an inverted alcohol series and mounted. 
3.4.3. Immunofluorescence staining 
 
Cells were grown on coverslips in 24-well plates and later washed with PBS and fixed 
using 4% paraformaldehyde for 10 minutes and washed again. 0.1% Triton X-100 was 
used for 10 min to permeabilize the cells followed by washing. For the blocking step, 
the cells were incubated in 10% BSA for 30 min followed by primary antibody overnight, 
4°C. On the following day, the cells were washed and incubated with the corresponding 
conjugated secondary antibody for 1h at room temperature. Washing was followed by 
incubation with DAPI in PBS for 5 min and mounting. Images were taken using the 
AXIO Scope.A1 microscope. 
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3.4.4. Flow cytometry 
The cells were treated with cyclosporine A or thapsigargin in different concentrations 
for 48 h on 6-well plates. After trypsinization, the cells were resuspended in 1 ml DMEM 
with 10% FCS,100 U/ml penicillin and 100 µg/ml streptomycin. 200,000 of filtered cells 
were collected by centrifugation at 350 g for 5 min and resuspended in 100 µl of a 
staining solution. To monitor EpCAM expression, the cells were stained with 2.5 µl 
FITC-anti EpCAM (Biolegend) conjugated antibody in 1 ml MACS buffer. After 20 min 
of incubation in the dark, the cells were centrifuged for 5 min, 350 g. The samples were 
resuspended in 500 µl MACS buffer and 200 µl of each sample were loaded in a 96-
well plate. FITC intensity was measured using the Guava EasyCyte plus (Guava 
Technologies) flow cytometer. 
3.5. Statistical analysis 
To create graphs, GraphPad Prism version 4.03 has been used for in this study. P-






Materials and methods (Section number 2 and 3) were prepared together for 
Chapter I and Chapter II part (Section number 4) of the thesis. The manuscript 
presented below was prepared based on Clinical Epigenetics Journal guidelines. In 
Chapter I and Chapter II short discussions are included. The overall discussion 
(General discussion) of all thesis results was shown below Chapter II. The overall 
references for all Chapters are indicated at the end of this thesis (Section Bibliography). 
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Reduction of PRC2/EZH2 activity can promote better survival of TNBC cancer 
cells in a context-specific manner 
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BACKGROUND: Breast cancer is the most common cancer occurring in women. 
Recent advances in early diagnosis and development of targeted therapies greatly 
improved the survival rate of breast cancer patients. However, conventional cytotoxic 
chemotherapies remain often the only treatment option for patients suffering from 
cancer subtypes where targeted therapies are not viable. Furthermore, the 
development of resistance is frequent and commonly followed by fatal consequences. 
In this study, we investigated epigenetic mechanisms underlying tumor cells surviving 
a combinatory chemotherapy treatment as potential targets to increase cytotoxic 
efficiency.  
 
METHODS: Murine basal-like WAP-T mammary carcinoma cells and human triple-
negative cell lines were utilized to study processes involved in cancer cell survival to a 
cyclophosphamide/doxorubicin/5-fluorouracil treatment. We performed high 
throughput RNA- and ChIP-sequencing analyses to assess transcriptome wide gene 
expression changes and underlying epigenetic regulatory mechanisms in cells 
surviving chemotherapy. To confirm our findings, we then employed several in vitro 
functional assay and corroborated our results on murine tissues and publicly available 
patient databases. 
 
RESULTS: Epithelial to mesenchymal transition (EMT) and increased stemness were 
tightly associated with survival of the cancer cells to chemotherapy. We identified a 
reduction of Polycomb Repressive Complex 2 (PRC2) activity via downregulation of the 
Ezh2, Suz12 and Rbbp7 expression in chemotherapy-treated WAP-T cells. 
Interestingly, siRNA and small molecule inhibition of PRC2 activity improved the 
proliferation and survival of murine and human cancer cells to cytotoxic treatment. 
Mechanistically, loss of PRC2 activity lead to the derepression of a set of genes through 
a switch from the repressive H3K27me3 to the activating H3K27ac mark at regulatory 
regions. We identified Nfatc1 as a gene upregulated by loss of PRC2 activity and 
directly implicated with the transcriptional changes happening upon survival the 
chemotherapy. Blocking NFATc1 activation reduced epithelial to mesenchymal 




CONCLUSIONS: Our data demonstrates a previously unknown function of PRC2 
maintaining low Nfatc1 expression levels and thereby repressing invasiveness of 
TNBC. 
 
KEYWORDS: PRC2, EZH2, TNBC, chemotherapy, H3K27ac, H3K27me3, NFATc1 
 
Background 
Breast cancer (also termed mammary carcinoma) is the most common 
cancerous disease in women with over 2 million new cases in 2018 worldwide (World 
Health Organisation, 2018). The mortality of breast cancer patients has significantly 
decreased over the past decades, mostly because of early diagnosis improvements 
and the development of several targeted therapies. However, despite intensive efforts 
to combat the disease, breast cancer remains the first cancer-related cause of death 
among women. The prognosis of cancer patients is largely determined by the 
metastatic lesions and recurrent tumor growth. Today, approximately 25% of breast 
cancer patients still develop distant metastases and ultimately die of their disease 
(Mathiesen et al., 2012). Even when detected early and treated by standard breast-
conserving surgery, breast cancer has a recurrence rate of 5-10% within 10 years 
(Colzani et al., 2014; Fisher et al., 2002; Harbeck et al., 2019; Veronesi et al., 2002). 
The high incidence of breast cancer and the high mortality rate of the disease in 
relapsed patients necessitates the urgent development of improved treatment options.  
Because of its highly heterogeneous nature, breast cancer is commonly 
classified into distinct disease subtypes with specific therapeutic approaches and 
outcome, based on expression of the receptor molecules ER (estrogen receptor) and 
PR (progesterone receptor) and HER-2 (human epidermal growth factor receptor 2) 
(Prat, Pineda, et al., 2015). Despite their great usefulness in the clinic, these 
histological parameters do not fully reflect the complexity of the disease. Progress in 
gene expression profiling lead to the definition of at least four different molecular 
subtypes of breast cancer with very different incidence, prognosis and response to 
treatments: Luminal A, Luminal B, HER-2 enriched and triple negative breast cancer 
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(TNBC) (Perou et al., 2000; Prat, Fan, et al., 2015). The possibility to specifically inhibit 
the activity of ER, PR and/or HER-2 via targeted therapies greatly improved the 
therapeutic options and prognosis of mammary carcinomas subtypes expressing those 
receptors. Unfortunately, because of the lack of ER/PR and HER-2 expression, the 
group of triple negative breast cancers (TNBC), that accounts for approximatively 15% 
of all mammary carcinomas do not profit from these therapeutic advances. Mammary 
carcinomas are clinically treated with a combination of surgery, radiation, 
chemotherapy and/or targeted therapies (if available) depending on the type and stage 
of the disease. Here, a combination of cyclophosphamide, anthracycline (doxorubicin) 
and/or 5-fluorouracil (5-FU) (CAF) have been shown to display an increase in 
pathological response rates in TNBCs compared to the other subtypes (Carey et al., 
2007; O. Gluz et al., 2009). Despite a good first response to cytotoxic therapies, a large 
fraction of TNBC rapidly develop resistance. Consequently, TNBCs show the highest 
rate of recurrence after treatment and the poorest prognosis among breast cancer 
diseases (Prat et al. 2015).  
Mechanisms allowing a tumor cell to escape conventional chemotherapeutic 
treatments require fast adaption to hostile conditions. Acquisition of epithelial-
mesenchymal plasticity (EMP) and stemness have been identified as potential 
mechanisms responsible for cancer progression, development of chemotherapy 
resistance and increased metastatic features (Lu and Kang 2019; Ye and Weinberg 
2015). Such alterable properties necessitate rapid reorganization of whole gene 
expression profiles. Because of the dynamic and reversible nature of epigenetic 
modifications, epigenetic processes represent very likely mechanisms controlling 
cellular plasticity. Thus, epigenetic players are attractive targets for the development of 
the new anti-cancer drugs (Mohammad et al. 2019; Wouters and Delwel 2016). 
Numerous publications reported the central role of epigenetic factors mediating the 
function of transcription factors during epithelial to mesenchymal transition (EMT) (Lu 
and Kang 2019; Wainwright and Scaffidi 2017). In a similar manner, epigenetic 
mechanisms were shown to be indispensable for the acquisition and maintenance of 
cancer stem cell (CSC) properties (Skrypek et al., 2017; Wainwright & Scaffidi, 2017). 
The Polycomb repressive complexes 1 and 2 (PRC1 and PRC2, respectively) are two 
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well characterized epigenetic factors repressing the expression of specific genes via 
histone post-translational modification. The canonical PRC2 core complex is composed 
of four subunits EZH1/EZH2, EED, SUZ12 and RBBP7. Through its catalytic subunit 
EZH2, the PRC2 catalyzes the di- and trimethylation of histone 3 at lysine 27 
(H3K27me2 and H3K27me3, respectively) promoting thereby a compaction of the 
chromatin, and as a consequence, leading to the silencing of genes located in the given 
region (Antonysamy et al., 2013; Simon & Kingston, 2013). Interestingly, PRC2 was 
shown to play an essential role in normal embryonal and adult stem cells homeostasis 
by maintaining self-renewal and pluripotency through repression of differentiation 
programs (Raphaël Margueron & Reinberg, 2011; Vizán et al., 2015). In line with these 
observations, higher EZH2 expression levels were associated with increased cancer 
stem cell properties and poor prognosis in numerous cancer entities including 
malignancies of the breast (Wen, Cai, Hou, Huang, & Wang, 2017). Furthermore, the 
enzymatic activity of the PRC2 complex was shown to actively promote EMT by 
positively regulating the expression of and cooperating with central EMT-transcription 
factors (EMT-TFs) like SNAI1 or ZEB1 (Herranz et al., 2008; Martínez-Fernández et 
al., 2015). 
In the past, we developed and characterized the WAP-T mammary carcinoma 
mouse model to study the biology, progression and metastatic processes of TNBC 
(Lenfert et al., 2015; Maenz et al., 2015; Otto, Gruner, et al., 2013; Otto, Streichert, et 
al., 2013; Schulze-Garg et al., 2000; Wegwitz et al., 2010). In a former effort to 
understand the effects of a CAF therapy on WAP-T mammary carcinomas, we 
observed that the cytotoxic combination therapy was not able to eradicate the disease 
in vivo. Interestingly, surviving tumor cells displayed a more aggressive mesenchymal-
like phenotype with increased stem cell traits and showed a pronounced tendency to 
dissemination (Jannasch et al., 2015). Because of its good mimicking of the clinical 
situation, we utilized this model in the present study to get insight into the molecular 
mechanisms underlying acquisition of EMP and stemness upon chemotherapy 
treatment and allowing tumor cell survival. We identified here a previously unknown 
PRC2 function repressing EMT and cancer stem cell program in TNBC cells along a 





WAP-T cells surviving CAF treatment gain stem cell and EMT properties in vitro. 
The parental G-2 cell line (pG-2), established from a WAP-T mammary 
carcinoma (Wegwitz et al., 2010) was utilized to investigate the effects of a CAF 
combination therapy on TNBC in vivo and it was observed that tumor cells surviving 
the therapy gained stemness and mesenchymal-like characteristics (Jannasch et al., 
2015). To get insights into the molecular pathways underlying the survival and the 
emergence of resistance to the CAF chemotherapy in vitro, we optimized in a first step 
the chemotherapy treatment settings of G-2 cells in the cell culture. Aim here was the 
identification of treatment conditions eradicating most of the tumor cells but allowing 
the survival and regrowth of a small tumor cell fraction, mimicking thereby the in vivo 
relapse situation. A combination therapy consisting of 312.5 ng/ml cyclophosphamide, 
15,6 ng/ml doxorubicin and 312,5 ng/ml 5-FU, corresponding to the 1/32 dilution of the 
therapy previously utilized in Jannasch et al in vivo, was identified as the best 
appropriate setting (Fig. I 1A). This treatment was adopted for the rest of the 
experiments in the present study and will be designated as CAF therapy. Interestingly, 
pG-2 cells surviving CAF-treatment acquired a more elongated morphology, 
characteristic for cells undergoing EMT (Fig. I 1B). A chemotherapy resistant variant of 
the pG-2 cells called rG-2 cells was established through several cycles of CAF 
treatments (see method section for more details). Strikingly, rG-2 cells harbor in basal 
growth condition a mesenchymal-like phenotype, supporting the potential implication 
of EMT mechanisms in resistance to CAF therapy (Fig. I S1A). We performed RNA-
sequencing (RNA-seq) and compared the transcriptome of pG-2 cells treated 48 hours 
with CAF to vehicle treated control cells (ctr). DeSeq2 analyses identified 1021 
downregulated and 1448 upregulated genes (|Log2(Fold Change)|>1, padj<0.05) in 
CAF-treated cells (Fig. I 1C). To get insights into transcriptional program changes 
occurring during survival to the treatment, we performed Gene Set Enrichment 
Analyses (GSEA). Strikingly, we observed a strong enrichment of gene sets related to 
EMT, cancer aggressiveness and stemness (Fig. I 1D). Indeed, the well-known EMT 
markers Vimentin (Vim) and N-cadherin (Cdh2) and EMT-TFs Snai1, Twist2 and Zeb1 
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were upregulated in surviving cells whereas the expression of both epithelial marker E-
cadherin (Cdh1) and Epcam were strongly reduced (Fig. I 1E). The regulation of Vim, 
Twist2, Snai1, Zeb1 and Cdh1 was validated using qPCR (Fig. I 1G). In a similar 
manner, the expression of stem cell specific transcription factors was also found to be 
increased in CAF-treated cells (Fig. I 1F). Interestingly, rG-2 cells showed increased 
expression of several EMT and stem cell markers under basal culture conditions (Fig. 
I S1B). These results support previous in vivo studies (Jannasch et al., 2015) and 







Fig. I 1 WAP-T cells surviving CAF treatment gain stem cell and EMT properties in vitro.  
A: Cell proliferation assay of pG-2 cells treated for 48 hours with increasing concentrations of a 
combinatory CAF chemotherapy. The concentration [1] represents the equivalent of the doses used in 
previous in vivo experiments (10 μg/ml cyclophosphamide, 0.5 μg/ml doxorubicin and 10 μg/ml 5-FU) 
(Jannasch et al., 2015). Cell confluency was assessed every day using Celigo. For a direct visualization, 
crystal violet staining was performed at day 2. B: Phase contrast images of pG-2 cells after 48 hours 
CAF-treatment showing a spindle like morphology characteristic for cells that underwent EMT (objective 
10x, scale bar = 250 µm). C: Volcano plot showing transcriptome wide gene expression changes in pG-
2 cells compared to pG-2 cells after 48 hours of CAF-treatment, as measured by RNA-seq (n=3 biological 
replicates). D: Representative GSEA enrichment plots showing a significant enrichment of gene 
signatures characteristic for EMT-processes, stemness traits and cancer invasiveness in CAF-treated 
versus control cells. E: Heatmap showing the regulation of selected EMT markers identified in the RNA-
seq analyses. F and G: Validation of EMT-marker regulation on protein level using western blot (F) and 
on mRNA level using qRT-PCR (G). qRT-PCR data was normalized to the control condition and 
normalized to the Rplp0. n=3 biological replicates +/- SEM, * p-val ≤ 0.05, ** p-val ≤ 0.01, *** p-val ≤ 
0.005. 
 
WAP-T tumor cells surviving CAF-treatment downregulate the expression of 
PRC2 core subunits 
We decided to get more insight into the molecular mechanisms allowing tumor 
cells to activate EMT and stemness transcriptional programs, increasing their 
aggressiveness and survival to cytotoxic therapies. We therefore returned to our GSEA 
analyses and interestingly identified an accumulation of gene signatures related to 
epigenetic regulatory pathways perturbation enriched CAF-treated cells (Fig. I 2A). This 
was an interesting finding, as several epigenetic mechanisms have been shown to be 
involved in the processes controlling cellular plasticity (Kiesslich, Pichler, & Neureiter, 
2012). Based on the RNA-seq results, we identified 65 down-regulated and 16 up-
regulated epigenetic factors (Fig. I 2B, listed in Table I S1). Surprisingly, Gene Set 
Enrichment Analysis (GSEA) and Enrichr analyses pointed at an enrichment of genes 
known to be H3K27me3-marked and/or repressed by PRC2 (Fig. I 2C). We therefore 
checked if changes of PRC2 subunits expression happened upon chemotherapy 
treatment. Strikingly, the core PRC2 subunits Ezh2, Suz12, Rbpp7 were found to be 
significantly downregulated in cells surviving the CAF treatment (Fig. I 2D). The down-
regulation of Ezh2, Suz12 and Rbbp7 was validated by qPCR (Fig. I 2E). On protein 
level, Ezh2 and Suz12 were reduced as assessed via western blots and 
immunofluorescence staining (Fig. I 2F-G). In line with these findings, rG-2 cells grown 
under normal conditions harbored a constant lower expression of the core PRC2 
subunits Ezh2, Suz12 and Rbbp7 when compared to untreated or treated pG-2 cells. 
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Noticeably, their expression levels were even more reduced upon CAF treatment (Fig. 
I S2). We concluded that the reduction of PRC2 level was associated with survival to 






Fig. I 2 WAP-T tumor cells surviving CAF treatment downregulate the expression of PRC2 core 
subunits. A: GSEA analysis results (MSigDB) plotted as an overview along Normalized Enrichment 
Score (NES) and log10(FDR). The results show an enrichment of gene signatures associated with 
epigenetic mechanisms perturbation. Blue dots represent enriched epigenetic pathway. B: Identification 
of differentially regulated epigenetic factors: genes regulated in pG-2 cells upon CAF treatment survival 
(|Log2(Fold Change)|>0.8, padj<0.05) were intersected with a list of known epigenetic factors. C: 
Representative GSEA enrichment plots showing the enrichment of gene signatures typically repressed 
by PRC2 in CAF-treated pG-2 cells. D: Heatmap showing the downregulation of central PRC2 members 
upon chemotherapy, as identified in the RNA-seq analyses, padj<0.05. E: Validation of Ezh2, Suz12 and 
Rbbp7 expression via qRT-PCR. Data was normalized on the control condition and normalized to the 
Rplp0 housekeeping gene. n=3 biological replicates +/- SEM, * p-val ≤ 0.05, ** p-val ≤ 0.01, *** p-val ≤ 
0.005.F and G: Reduction of EZH2 and SUZ12 protein levels upon CAF treatment was assessed via 
western blot (F) and immunofluorescence staining (G).  
 
Reduction of EZH2 activity enhances the aggressiveness of TNBC tumor cells  
Although the majority of the literature attributes rather tumor promoting functions to the 
PRC2 complex, a few recent publications have pointed towards a possible tumor suppressive 
role in ovarian carcinoma (Cardenas et al., 2016). We therefore asked whether the 
reduction of PRC2 activity could directly mediate WAP-T tumor cell survival to cytotoxic 
therapies by derepressing aggressive and/or proliferative gene expression programs. 
To assess the effect of EZH2 activity loss on the proliferation of pG-2 cells, we silenced 
Ezh2 using targeted siRNA or treated the cells with a small molecule inhibitor against 
EZH2 (EPZ-6438) and performed proliferation assays. Interestingly, impairment of 
EZH2 activity did not reduce proliferation of the tumor cells as it was observed for 
numerous other BC cell lines in the past (Gonzalez et al., 2009; Song et al., 2016). On 
contrary, the growth of pG-2 cells was slightly but significantly promoted upon EZH2 
knockdown (Fig. I 3A) and low concentrations of EPZ-6438 (Fig. I 3D). Ezh2 
knockdown efficiency was validated at mRNA level (Fig. I 3B) and loss of H3K27me3 
resulting from EPZ-6438 treatment was measured by western blot for different 
concentrations (Fig. I 3C). Interestingly, colony formation ability of pG-2 cells seeded 
at limiting dilution was strongly improved upon inhibition of EZH2, suggesting increased 
tumor initiating properties (Fig. I 3E). Strikingly, this increased colony formation 
capacity was maintained upon chemotherapy treatment, indicating that the inhibition of 
the PRC2 complex activity indeed supported cell survival and resistance to the therapy 
(Fig. I 3E). We asked whether this observation was limited to the murine WAP-T 
mammary carcinomas or if other human cancer cell lines could also get a growth and 
survival advantage upon PRC2 activity loss. Interestingly, although certain breast 
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cancer cell lines showed impaired or unchanged proliferation upon EZH2 inhibition, the 
MDA-MB-468 TNBC cell line displayed moderate but increased growth properties when 
treated with siRNA against EZH2 or with EPZ-6438 (Fig. I S3). Interestingly, the 
proliferation stimulating consequence of an EZH2 inhibition was not limited to breast 
cancer cell lines, but was also observed in human cancer cell lines of other origins, 
colorectal and bile duct carcinoma (Fig. I S4). Moreover, the proliferation advantage 
mediated by EZH2 knockdown in MDA-MB-468 was even more pronounced in the 
presence of CAF treatment (Fig. I S3B). Together, inhibition of PRC2 repressive activity 
increases aggressiveness of cancer cells and increases cytotoxic therapy survival in a 




Fig. I 3 Reduction of EZH2 activity enhances the aggressiveness of TNBC tumor cells. 
A: Crystal violet staining of pG-2 cells upon Ezh2 knockdown. The confluency was measured by ImageJ 
and normalized to the controls. B: Validation of Ezh2 knockdown efficiency using qRT-PCR. Data were 
calibrated to the control condition and normalized on the Rplp0. C: Assessment of EZH2 inhibition by 
H3K27me3 levels upon increasing EPZ-6438 concentration using western blot. D: Proliferation assay of 
EPZ-6438-treated pG-2 cells using Celigo® and crystal violet staining. E: Colony formation assay upon 
treatment of pG-2 cells with EPZ-6438 alone or in combination with CAF. Number of colonies were 
assessed through ImageJ analysis. n=3 biological replicates +/- SEM, * p-val ≤ 0.05, ** p-val ≤ 0.01, *** 




Reduction of PRC2 activity during chemotherapy treatment enables the 
activation of gene expression programs promoting tumor cell survival. 
The trimethylation of H3K27 by PRC2 mediates the silencing of chromosomal 
regions by promoting chromatin compaction through cooperation with the PRC1 
complex (Grossniklaus & Paro, 2014). Furthermore, because of the occupancy of the 
presence of the methyl groups, H3K27me3 is mutually exclusive with the transcriptional 
activating mark H3K27ac (Tie et al., 2009). Relying on this knowledge, we 
hypothesized that loss of PRC2 activity during chemotherapy survival could lead to an 
epigenetic switch enabling tumor cells to activate translational programs promoting 
aggressiveness and therapy resistance. To test our hypothesis, we assessed genome 
wide changes of H3K27me3 and H3K27ac occupancy via ChIP-seq in untreated as 
well in 48 and 96 hours CAF-treated pG-2 cells. Because we suspected a direct 
connection between PRC2 repressive activity loss and activation of genes expression 
programs upon CAF treatment, we decided to investigate the changes of H3K27me3 
and H3K27ac at the TSS region of upregulated genes. As presumed, the levels of 
H3K27me3 at promoter regions of up-regulated genes were significantly reduced 
already after 48 hours and remained low after 96 hours (Fig. I 4A). This analysis 
uncovered a switch from H3K27me3 to H3K27ac indicating potential genes activated 
through PRC2/EZH2 loss. H3K27ac as a mark of active promoters and active gene 
transcription, we observed its increased level upon chemotherapy. In this analysis, 74 
genes showed at the same time a robust up-regulation at the RNA level (Log2FC > 0.8, 
p-val < 0.05) and a switch from trimethylation to acetylation at H3K27 (Fig. I 4B). 
Moreover, we identified a number of upregulated genes with subsequent loss of 
H3K27me3 and H3K27ac gain (Fig. I 4C). We selected few of them with the most 
relevant H3K27me3/H3K27ac change at promoter regions, such as Nfatc1, Wnt9a, Gli2 
and Klf4 (Fig. I 4C, D). Additionally, RNA-seq results presented on the heatmap, shows 
a characteristic upregulation of the aforementioned genes (Fig. I 4D). To investigate 
enrichment signatures between CAF-treated (48h) and control cells, we used the online 
Enrichr tool (Fig. I 4E). One of the most significantly enriched pathways, was calcineurin 
signaling involving NFATc1. NFATc1 activation was shown to promote EMT and tumor 
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progression in several tumor entities. Furthermore, Chen et al. reported a context 
dependent epigenetic regulation of NFATc1 expression by EZH2 in pancreatic tissues 
(N. M. Chen et al., 2017). Additionally, NFATc1 can be targeted by small molecule 
inhibitors, some of them being commonly employed in the clinic (e.g. Cyclosporin A, 
CsA), making this factor very attractive to study in the context of survival and resistance 
to chemotherapy (Pan, Xiong, & Chen, 2013).  Upregulation of Nfatc1 upon CAF-
chemotherapy treatment was confirmed on mRNA (Fig. I 4F) and protein level (Fig. I 





Fig. I 4 CAF-chemotherapy-induced epigenetic regulation in pG-2 cells. A: Aggregate plots of 
H3K27me3 and H3K27ac ChIP-seq signals at ±5 kb of the TSS) of genes that were upregulated (RNA-
seq) upon CAF-chemotherapy treatment for 48 hours (48, light blue line), treated with CAF-
chemotherapy for 48 hours and fresh medium for the next 48 hours (96, dark blue line) and untreated 
(ctr, yellow line).  B: Venn diagram showing the overlap of the H3K27me3 loss and the H3K27ac gain 
ChIP-seq peaks with upregulated genes, 0.8≤log2(FC), from RNA-seq data. C: H3K27me3 and 
H3K27ac ChIP-seq tracks at Nfatc1, Wnt9a, Gli2 and Klf4 gene loci in CAF-chemotherapy treated (48h, 
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96h) and control cells (0h). H3K27me loss and H3K27ac gain at promoter region, indicated in blue boxes 
D: RNA-seq heatmap of selected upregulated genes upon 48 hours CAF treatment. E: Enrichr analysis, 
BioCarta for the most significant pathways, on the 74 identified genes from Fig. I 4B. F: Expression of 
Nfatc1 on mRNA, +/- SEM, * p-val ≤ 0.05, ** p-val ≤ 0.01, *** p-val ≤ 0.005 and G: protein level in 48 
hours CAF-treated pG-2 cells. 
 
EZH2 loss mediates NFATc1-induced cancer progression in TNBC 
 To investigate whether EZH2 modulates NFATc1 expression, we performed 
knockdown of Ezh2 in pG-2 cells. Upon Ezh2 loss, we observed a decrease in 
H3K27me3 and a Nfatc1 upregulation, meaning that EZH2 activity negatively 
modulates NFATc1 expression (Fig. I 5A). To further analyze Ezh2 and Nfatc1 
expression in vivo, we used WAP-T mice tumors followed by CAF treatment (Fig I 5B). 
IHC staining revealed a loss of EZH2 and an upregulation of NFATc1 in the acute phase 
of CAF treatment. Whereas during the recovery phase, Ezh2 expression increased and 
Nfatc1 level came back close to the basal level (control) indicating rapid changes in 
gene expression upon cytotoxic stimuli. Based on human primary breast tumors, gene 
expression signature analysis also suggests a frequent negative correlation between 
EZH2 and NFATc1 (Fig. I 5C). Additionally, we used The Cancer Genome Atlas 
(TCGA) PAM50-based database for human TNBCs where we could observe differential 
EZH2, NFATc1 expression among patients (Fig. I 5D). Interestingly, survival plots using 
patients data with low or high expression of EZH2 (left) and NFATc1 (right) (Fig. I 5E) 
suggest that patients survival is positively correlated with EZH2 expression and 
negatively correlated with NFATc1. These data suggest that NFATc1 can be a potential 




Fig. I 5 Differential expression of Ezh2 and Nfatc1 in TNBC. A: Nfatc1 regulation upon loss of EZH2 
in protein level in pG-2 cells. B: Representative images of paraffin-embedded tumors from Group 1: 
dissected when tumors reached 0.5 cm3, Group 2: CAF treated and dissected after 9 days and Group 3: 
CAF treated and dissected when reaching initial tumor volume, stained for Ezh2 and Nfatc1. C: Gene 
expression signature of Ezh2 and Nfatc1 using MERAV presented with Pearson correlation that is -0.21 
in primary breast tumors. D: TCGA PAM50 (Xenabrowser)-based scatter plot with linear regression of 
the genome-wide correlation between EZH2 and NFATc1. E: TCGA PAM50-based survival of TNBC 







NFATc1 knockdown decreases TNBC cell invasiveness 
 NFAT proteins have been shown to be involved in EMT processes in breast 
cancer (Sengupta et al., 2013). In this part of the study we wanted to verify NFATc1 
function in TNBC and investigate its involvement in cancer cell motility, growth, EMT 
and stemness. Nfatc1 knockdown decreased pG-2 cell growth (Fig. I 6A, B), where 
Nfatc1 loss efficiency was confirmed on mRNA (Fig. I 6C) and protein level (Fig. I 6D). 
Additionally, we observed great proliferation impairment upon NFATc1 depletion alone 
or in combination with CAF in the human breast cancer cell line, MDA-MB-468 (Fig. I 
S5). In pG-2 cells, Nfatc1 loss lead to reduced migratory ability (Fig. I 6E, F). Based on 
the findings on epithelial-mesenchymal plasticity (EMP) of metastatic breast cancer and 
our previously shown data (Fig. I 1), we analyzed EMT-related markers in the context 
of Nfatc1 regulation. Our data demonstrate that upon loss of Nfatc1, TNBC cells change 
to a more epithelial phenotype (Fig. I G, H). In addition, we treated pG-2 cells with 
cyclosporine A (CsA) and Thapsigargin to inhibit and stimulate Nfat activity, repectively 
(Fig. I 6H, Fig. I S6). The cells were treated with increasing concentrations of CsA and 
Thap for 48 hours, stained with FITC conjugated antibody against EpCAM. We 
observed an increase and a decrease in EpCAM-positive cells upon CsA and Thap 
treatment respectively, suggesting a key role of Nfatc1 in EMT and indicating its 




Fig. I 6 Nfatc1 inhibition and knockdown abrogates oncogenic properties of TNBC cells. A: 
Suppression of cell growth upon Nfatc1 knockdown determined by Celigo and B: crystal violet. C: 
Knockdown of Nfatc1 was validated on mRNA and D: protein level. E: Reduced migration capacity upon 
Nfatc1 knockdown assesed using Boyden chamber assay and F: scratch assay. G: Regulation of EMT 
markers upon Nfatc1 knockdown on mRNA level,n=3 +/- SEM, * p-val ≤ 0.05, ** p-val ≤ 0.01, *** p-val ≤ 
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0.005. H: FACS showing an increase of EpCAM positive cells upon inhibition of Nfatc1 via cyclosporine 




 In contrast to early and locally constrained breast cancer, advanced metastatic 
disease is often considered as incurable (Harbeck et al., 2019). For this reason, 
therapies of cancers in advanced stages mainly focus on patient survival and life quality 
improvement. Because of the lack of specific therapeutic targets, treatment of 
advanced TNBC almost exclusively relies on the efficiency of cytotoxic therapies, while 
also being prone to resistance. Hence, a better understanding of the mechanisms 
leading to chemotherapy resistance represents a crucial step for the development of 
more efficient therapeutic approaches. In the present study, we utilized the murine 
WAP-T mammary carcinoma cell system to model and investigate molecular 
mechanisms underlying TNBC survival to conventional chemotherapy. Our 
transcriptome wide analyses showed that WAP-T cells activate transcriptional 
programs characteristic for EMT and cancer stem cells during survival to treatment. 
Interestingly, gain of epithelial-mesenchymal plasticity was shown to promote tumor 
cells invasiveness and protect them from pro-apoptotic signals (Kalluri & Weinberg, 
2009; Scheel & Weinberg, 2011). Additionally, EMT and CSC properties are tightly 
linked together and have been frequently shown to positively influence each other 
(Hennessy et al., 2009; Loret, Denys, Tummers, & Berx, 2019; Mani et al., 2008). 
Notably, both EMT and CSC properties were implicated in the acquisition of 
chemotherapy resistant phenotypes by the tumor cells (Izumiya et al., 2012). In order 
to develop resistance, cell have to rapidly and profoundly reorganize their 
transcriptional programs. Therefore, because of their very dynamic nature, we 
expected epigenetic mechanisms to be involved. Combining mRNA-seq and ChIP-seq 
approaches, we identified a reduction of the PRC2/EZH2 activity occurring during 
chemotherapy survival in WAP-T cells. Interestingly, the repressive activity of EZH2 on 
gene expression is mostly known to promote cancer progression and contribute to 
therapy resistance in various types of cancer (Hirukawa et al., 2018; Hu et al., 2010; 
Kikuchi et al., 2015; Zhang et al., 2013). Specifically, EZH2 activity was implicated in 
resistance to programmed cell death in TNBC (J. P. Huang & Ling, 2017; P. Zhang et 
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al., 2018). Paradoxically, our results unraveled an opposite role of PRC2/EZH2 in 
TNBC cells, maintaining a more chemotherapy sensitive phenotype via specific 
repression of EMT and CSC transcriptional programs. Although apparently 
contradictory at the first glance, our results align with still scarce but growing evidences, 
that loss of PRC2/EZH2 activity can drive or support initiation and progression of 
cancers in a context specific manner (Vo et al., 2017; Wassef et al., 2015). In 2015, the 
group of Raphaël Margueron elegantly demonstrated that reduced EZH2 expression 
promotes transcriptional instability and is likely to promote breast tumorigenesis 
(Wassef et al., 2015). Shortly later, Serresi and colleagues showed in two consecutive 
studies on Non-Small-Cell-Lung Cancer that PRC2 activity can act as a barrier to 
KRAS-driven inflammation and EMT (Serresi et al., 2016). Our investigations on murine 
and human TNBC cell lines corroborated these observations and described thereby a 
new molecular mechanism by which PRC2/EZH2 can exert its repressive function on 
the EMT transcriptional program. Specifically, loss of PRC2 subunits upon 
chemotherapy treatment leads to a rapid upregulation of central EMT regulators via a 
repressive (H3K27me3) to activating (H3K27ac) epigenetic switch. Strikingly, we 
identified here NFATc1 as one of the major EMT-TF under the immediate epigenetic 
control of PRC2 in TNBC and upregulated in cells surviving chemotherapy. 
Interestingly, the group of Hessmann reported that NFATc1 is needed for pancreas 
during regeneration after injury and is epigenetically silenced by EZH2 activity once 
regeneration is completed, supporting the mechanism of regulation identified in the 
present study (N. M. Chen et al., 2017). The pivotal role of NFATc1 in the activation of 
EMT transcriptional programs in cancer cells and the availability of specific small 
molecule inhibitors (e.g. cyclosporine A or VIVIT) renders this factor a very interesting 
potential drug target to increase conventional therapies efficiency (Aramburu et al., 
1999; F. Liu et al., 2009). In this study, we observed an increased efficiency of CAF 
treatment on TNBC cells when co-treated with cyclosporine A or VIVT. These results 
are in line with former studies on lung cancer, acute myeloid leukemia (AML) and 
bladder cancer showing that NFATc1 inhibition sensitized cancer cells to cisplatin, 
sorafenib- and tacrolius-induced apoptosis, respectively (Im et al., 2016; Kawahara et 





This study presents the evidence of a context dependent PRC2/EZH2 function 
in breast cancer that in certain circumstances can sensitize the cells to chemotherapy 
by epigenetically repressing NFATc1 expression. Our data suggests that targeting 
NFATc1 signaling in TNBC patients with low EZH2 expression could increase the 
efficiency of conventional chemotherapeutic treatments and reduce the development 





Fig. I S1 WAP-T cells surviving CAF treatment with EMT and stemness changes in vitro. A: Phase 
contrast images of rG-2 cells 48 hours after CAF-treatment show (objective 10x, scale bar = 250 µm). 
B: EMT markers expression on mRNA level in pG-2 and rG-2 cells, n=3, normalized to Rplp0, +/- SEM, 
* p-val ≤ 0.05, ** p-val ≤ 0.01, *** p-val ≤ 0.005.  
 
 
Fig. I S2 Regulation of PRC2 members in pG-2 and rG-2 cells upon 1/32 chemotherapy treatment. 
A: Relative mRNA expression of Ezh2, Suz12 and Rbbp7 upon 48 h of CAF treatment, n=3, normalized 
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to the Rplp0 housekeeping gene, +/- SEM, * p-val ≤ 0.05, ** p-val ≤ 0.01, *** p-val ≤ 0.005. B: 
Immunofluorescence staining of Ezh2 and Suz12 in CAF-treated rG-2 cells, corresponding to Fig. I 2G.  
 
 
Fig. I S3 EZH2 inhibition and knockdown in MDA-MB-468 cells. A: Proliferation assay of EPZ-6438-
treated MDA-MD-468 cells using Celigo (left) and crystal violet staining at day 7 (right). B: Proliferation 




Fig. I S4 EZH2 inhibition in human colorectal and bile duct carcinoma cell lines. Proliferation assay 
of HCT116 and HT29 (colorectal cancer), TFK1 and EGI-1 (bile duct carcinoma) cells treated with 





Fig. I S5 NFATc1 knockdown in MDA-MB-468 cells treated with and without 1/32 CAF-
chemotherapy. Proliferation assay of EPZ-6438-treated MDA-MD-468 cells using Celigo (left) and 
crystal violet staining at day 7 (right). 
 
 
Fig. I S6: Inhibition and activation of NFATc1 leads to epithelial-mesenchymal phenotype 
changes in pG-2 cells. pG-2 cells were treated for 48 h with different concentrations of cyclosporine A 
(CsA) or thapsigargin (Thap), harvested and stained with the conjugated antibody FITC-EpCAM, and 
analyzed by flow cytometry. 
  
Table I S1. Epigenetic regulators list 
AIRE CBX2 DPF2 JARID2 L3MBTL3 NSD1 PRDM
11 
SETD1A SMYD5 















ARID4B CBX6 EED JMJD4 MBD1 PAF1 PRDM
15 
SETD4 SP140L 
ASF1A CBX7 EHMT1 JMJD6 MBD2 PBRM1 PRDM
16 
SETD5 SRCAP 











ASH2L CDC73 EP300 KAT2A MBD5 PCGF2 PRDM
5 
SETD8 SUPT6H 
ASXL1 CDY1 EP400 KAT2B MBD6 PCGF3 PRDM
6 
SETD9 SUPT7L 












ATAD2B CDYL EZH2 KAT7 MGMT PHC2 PRMT1 SFMBT1 SUV420
H2 
ATRX CDYL2 FANCL KAT8 MINA PHC3 PRMT1
0 
SFMBT2 SUZ12 





FBXO11 KDM1B MLLT6 PHF10 PRMT3 SIN3A TAF1 
BAZ1A CHAF1
B 
G2E3 KDM2A MORC3 PHF11 PRMT5 SIN3B TAF1L 
BAZ1B CHD1 GADD4
5A 
KDM2B MORC4 PHF12 PRMT6 SIRT1 TAF3 
BAZ2A CHD1L HAT1 KDM3A MORF4L1 PHF13 PRMT7 SIRT2 TAF8 










KDM4B MSL3L1 PHF16 PYGO
1 
SKB1 TET2 





BRD2 CHD6 HDAC3 KDM4D MTA2 PHF19 RAG2 SMARCA
2 
TRIM24 
BRD3 CHD7 HDAC4 KDM4E MTF2 PHF2 RBBP4 SMARCA
4 
TRIM28 
BRD4 CHD8 HDAC5 KDM5A MYSM1 PHF20 RBBP7 SMARCA
5 
TRIM33 





















BRDT CXXC1 HDAC9 KDM6A NAP1L1 PHF23 RNF20 SMARCC
1 
UHRF2 










HTATIP KMT2A NAP1L4 PHF6 RSF1 SMARCD
2 
WDR82 


























CARM1 DOT1L ING5 L3MBT
L1 
NCOA2 PRDM1 SCML2 SMYD3 ZCWPW
2 




SET SMYD4 ZMYN11 




Erich und Gertrud Roggenbuck-Stiftung zur Förderung der Krebsforschung. 
 
Acknowledgements 
The authors would like to thank the group of Prof. Johnsen for constructive 
discussions and help.  
 
Contributor Information 
Iga K. Mieczkowska, iga.dudzicz@med.uni-goettingen.de 
Geske E. Schmidt, geske.schmidt@med.uni-goettingen.de 
Lukas C. Müller-Kirschbaum, l.muellerkirschbau@stud.uni-goettingen.de 
Garyfallia Pantelaiou, gar_pantelaiou@yahoo.gr 
Evangelos Prokakis, eprokak@gwdg.de 
Taras Velychko, taras.velychko@gmail.com 
Frauke Alves, falves@gwdg.de 
Madhobi Sen, madhobi.sen@zentr.uni-goettingen.de 





4.2. Chapter II Report 
 
Therapeutical potential of HDACs in chemotherapy resistance in triple-negative 
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The most commonly diagnosed cancers in women are malignancies of the 
breast (World Health Organisation, 2018). Triple-negative breast cancer (TNBC) is the 
most aggressive and heterogeneous breast cancer subtype (Perou et al., 2000). Due 
to lack of estrogen receptor (ER) progesterone receptor (PR) and human epidermal 
growth factor 2 (HER2) expression, chemotherapy treatment is one of the most 
common therapy in TNBC. Conventional chemotherapy including platinum agents, 
such as carboplatin and cisplatin, paclitaxel or 5-fluorouracil before or after surgical 
resection remain the standard approach in the clinic (Isakoff, 2010; Sirohi et al., 2008).  
Unfortunately, cancer relapse occurs quite frequently among TNBC patients 
followed by chemotherapy (O’Reilly et al., 2015). Epigenetic changes are involved in 
chemotherapy resistance as many studies and our previous data report (Mieczkowska 
et al., 2019, unpublished, J. Han et al., 2019; Pineda et al., 2019). Histone deacetylases 
(HDACs) are a class of epigenetic regulators very frequently altered in cancers 
including breast cancer (Krusche et al., 2005; K. M. Sakamoto & Aldana-Masangkay, 
2011; Shan et al., 2017). HDACs modulate the gene expression by among other 
controlling the deacetylation/acetylation balance at lysine residues of histones, together 
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with histone acetyltransferases (HAT), (Grunstein, 1997). The deacetylation of histones 
leads to chromatin condensation resulting in repression of transcription (Roth et al., 
2001). We can distinguish four classes of HDAC family: class I (HDAC1, -2, -3 and -8), 
class IIa (4, -5, -7 and -9), IIb (HDAC6 and -10), class III (sirtuins) and class IV 
(HDAC11) (Gregoretti et al., 2004; Seto & Yoshida, 2014). HDAC-triggered abnormality 
in pivotal gene expression can lead to tumor invasiveness (Richon et al., 2000). As a 
consequence, anti-cancer potential of therapeutic strategies targeting HDACs have 
been several times demonstrated in vitro and in vivo, therefore being very attractive for 
the development of novel drugs (Bolden et al., 2006). The best studied and FDA-
approved pan-HDAC inhibitors are Vorinostat (SAHA) and Panobinostat (LBH-589), 
both strongly targeting HDACs class I and II (Duvic et al., 2007; San-Miguel et al., 2013; 
Stahl et al., 2016). HDACs inhibitors are clinically used for cutaneous T-cell lymphoma 
(CTCLs) (Lopez et al., 2018). Using HDACs inhibitors improved patient outomes with 
myeloma. However, beneficial therapeutical effects were not obtained in solid tumors 
(Bolden et al., 2006).  
In TNBC, SAHA was reported as the most promising therapeutic treatment, 
however its efficiency is limited as a single drug (Garmpis et al., 2017). In the present 
project, we identified an upregulation of Hdac4, Hdac7 and Hdac8 in murine WAP-T 
TNBC cells surviving a cytotoxic therapy. We therefore aimed to study the potential of 
treatments specifically targeting one of these HDACs and to determine possible 




CAF chemotherapy-induced EMT changes in TNBC 
We previously showed that WAP-T cells (pG-2) surviving a CAF 
(Cyclophosphamide, Doxorubicin/Adriamicin, and 5-Fluorouracil/5-FU) chemotherapy 
treatment adopted a more mesenchymal phenotype, pointing at an involvement of 
epithelial-to-mesenchymal transition program in the chemotherapy resistance 
(Mieczkowska et al., 2019, manuscript under submission). To determine if human 
TNBC cells undergo similar transcriptional program changes upon survival to cytotoxic 
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therapies, HCC1806 cells where treated with increasing concentrations of a CAF-
chemotherapy as well as cisplatin and paclitaxel. Concentration of 2.5 µM cisplatin, 2.5 
nM paclitaxel and 1/16 CAF (30 ng/ml Cyclophosphamide, 0.62 µg/ml Doxorubicin, 
0.62 µg/ml 5-FU) showed the optimal results for our purpose (Fig II S1), killing the vast 
majority of the cells, while allowing the regrowth of more resistant cell phenotypes (Fig 
II 1A). Strikingly, gene expression analyses of treated HCC1806 cells identified an 
increased expression of mesenchymal markers (SNAI1, N-CADHERIN, VIMENTIN) in 
cells surviving the different treatments, pointing at the occurrence of an EMT also in the 






Figure II 1. A: Human TNBC cells undergo EMT upon survival to different cytotoxic treatments. 
24 hr after seeding, the cells were treated with either 1/16 CAF (30 ng/ml Cyclophosphamide, 0.62 µg/ml 
Doxorubicin, 0.62 µg/ml 5-FU), 2 µM cisplatin or 2.5 nM paclitaxel for 48 hours. A: bright field pictures of 
HCC1806 upon various chemotherapy treatments. Microscope: Nikon ECLIPSE TS100-F with 4x 
objective. B: Gene expression analysis of EMT markers in HCC1806 cell line upon treatment, assessed 
by qRT-PCR. mRNA expression values were normalized to the housekeeping gene expression Rplp0 
and calibrated to the respective untreated controls. Average mRNA expression values are given ± 
standard deviation (SD). Experiments were conducted in biological duplicates (n = 2) with technical 
triplicates. *: p < 0.05; **: p < 0.01. 
 
In our previous work, mRNA-sequencing (mRNA-seq) analyses were performed 
to study the mechanisms involved in WAP-T cell survival to chemotherapy 
(Mieczkowska et al., 2019, manuscript under submission). We thereby identified the 
enrichment of EMT and cancer stem cell (CSC) signatures signature accompanying 
more resistant WAP-T cancer cell phenotypes. Interestingly, signatures pointing at 
epigenetic dysregulations were enriched. As epigenetic regulatory pathway are known 
to control EMT- and CSCs – transcriptional programs (Lu & Kang, 2019) we focused 
on the regulation of epigenetic factors upon CAF treatment. Here, we observed that the 
majority of these factors were down-regulated (n=64) and that only a few were 
upregulated (n=16). We notably observed that Hdac4, Hdac7 (class IIa) and Hdac8 
(class I) figured among the upregulated genes.  Hdac4, -7 and -8 overexpression was 
reported to be associated with poor survival and tumor invasiveness (Hsieh et al., 2016; 
Zeng et al., 2016; Zhu et al., 2011). We performed qRT-PCRs on pG-2 and rG-2 cells, 
a chemoresistant resistant variant of the parental pG-2 cell line (Mieczkowska et al., 
2019, manuscript under submission), to validate our findings. Indeed, CAF treatment 
of pG-2 cells increased mRNA expression levels of Hdac4, and its levels were 
maintained high in the resistant cells, independent of treatment. Hdac7 was almost 
three times upregulated in treated parental cells. Interestingly, rG-2 cells displayed 
sensibly the same high levels of Hdac7 expression as treated pG-2 cells and its 
expression even stronger upon cytotoxic treatment. Finally, levels of Hdac8 were only 
moderately upregulated upon CAF treatment of parental cells and its levels were only 
significantly higher in the treated resistant cells. Taken together, we confirmed the 
upregulation of Hdac4, 7 and 8 upon cytotoxic treatment and observed that high levels 
of these genes are associated with resistant phenotypes. We therefore asked if 
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interfering with these factors via siRNA mediated silencing would impact the growth 
and resistance properties of these cells. We therefore performed crystal violet staining 
and found that loss of Hdac4, -7 and -8 slightly reduced the proliferation of pG-2 cells 
and only marginally the proliferation of rG-2 cells, when cultured under normal 
conditions. Strikingly, the proliferation of pG-2 and rG-2 was much stronger affected by 
siRNA treatment when co-treated with low doses of CAF (Fig. II 2C), pointing at a 






Figure II 2. Upregulation of Hdac4, -7 and -8 upon CAF-chemotherapy treatment in G-2 cells is 
necessary for their survival. A: Heatmaps showing epigenetic factors (left panel) and several Hdac 
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genes (right panel) significantly regulated upon 48 hours CAF treatment (312,5 ng/ml cyclophosphamide, 
15,6 ng/ml doxorubicin and 312,5 ng/ml 5-FU) in pG-2 cells (p adjusted value < 0.05, n = 3 biological 
replicates). Expression values are displayed as Z-score. B: Validation of Hdac4, Hdac7 and Hdac8 gene 
regulation in pG-2 and rG-2 cells (ctr) upon 48 hours CAF. mRNA expression values were normalized to 
the housekeeping gene Rplp0 and to the respective untreated controls. Average mRNA expression 
values are given ± standard deviation (SD). Experiments were conducted in biological duplicates (n = 3). 
T-test: * p < 0.05; ** p < 0.01; *** p < 0.001. C: Proliferation assay using crystal violet staining upon 
Hdac4, Hdac7 and Hdac8 knockdown in pG-2 and rG-2 cell lines with or without CAF treatment (CAF), 
n=2 biological replicates. 
 
EMT modulation and TNBC cell survival upon HDAC4, -7 and -8 loss 
 To extend our results to the human situation, we examined the influence of 
HDAC4, -7 and -8 loss in human HCC1806 cells. Decreased cell growth rate under 
normal conditions was observed upon HDAC4, -7 and -8 knockdown (Fig. II 3A). 
Interestingly, in a similar manner as for murine cells, we observed a clear sensitization 
of the human TNBC cells to low concentration of CAF treatment (1/256) when 
combined with HDAC4, -7 and -8 knockdown (Fig. II 3B). We next asked whether 
depletion of HDAC4, 7 or 8 in human cells could also result in an impairment of the 
EMT transcriptional program. Surprisingly, we observed that solely HDAC8 loss lead 







Figure II 3. Impact of HDAC4, -7 and -8 loss in HCC1806 cells. A and B: Proliferation assays of 
HCC1806 cells upon HDAC4, -7 and -8 knockdown with or without CAF-treatment (30 ng/ml 
Cyclophosphamide, 0.62 µg/ml Doxorubicin, 0.62 µg/ml 5-FU), assessed via crystal violet staining (A) 
and Celigo cell cytometer measurement.  C: Proliferation assays of HCC1806 cells upon HDAC4, -7 and 
-8 knockdown with or without low dose of CAF-treatment (1/256), assessed via Celigo D: Gene 
expression analysis of EMT markers in HCC1806 cell line using qRT-PCR. mRNA expression values 
were normalized to Rplp0 and to the respective untreated controls. Average mRNA expression values 




Following, we examined the potential of a co-treatment with chemotherapy and 
HDAC inhibitors in TNBC. Although silencing of HDAC4 and HDAC7 sensitized pG-2 
and HCC1806 cells to cytotoxic therapies, the well-established HDAC class II inhibitors 
TMP269 and TMP195 inhibiting both HDAC4 and -7 could not impair cell viability when 
combined with CAF, cisplatin or paclitaxel (data not shown). As only HDAC8 loss 
reduced EMT induction in HCC1806, we decided to investigate the clinical potential of 
HDAC8 inhibition using PCI-34051 in combination with cytotoxic drugs in pG-2  (Fig. II 
4 A) and rG-2 cells (Fig. II 4B). In pG-2 cells, we could observe a sensitization to the 
therapy when PCI-34051 and CAF-chemotherapy were combined. Moreover, HDAC8 
inhibition alone and in combination with CAF lead to significant cell growth impairment 
in the resistant rG-2 cells. Together, our findings identified HDAC8 as an attractive 




Figure II 4. Suppression of cell growth upon HDAC8 inhibition in murine TNBC cell lines. A and 
B: Cell proliferation assay in pG-2 (A) and rG-2 cells (B) upon 5 µM PCI-34051 treatment alone (left 
panel) or combined with 48 hours CAF-chemotherapy (1/32), followed by fresh medium culturing G-2 







Figure II S1. Proliferation assay using crystal violet staining upon different chemotherapy 
concentrations in HCC1806 cell line. Cells were treated with chemotherapy 24 hours after seeding 
and were allowed to grow over 1 week. Concentration [1] for CAF is representing 0.5 µg/ml 
cyclophosphamide, 10 µg/ml doxorubicin, and 10 µg/ml 5-FU combination. 
 
Discussion 
 TNBC is one of the most difficult cancers to treat, due to its heterogeneity and 
high cancer relapse rate (World Health Organisation, 2018). EMT was identified as a 
mechanism involved in overcoming cytotoxic treatments in TNBC cancer cells. EMT is 
cellular process modulated through epigenetic modifiers, like HDACs (R. Chang, You, 
& Zhou, 2013; Lei et al., 2010). Despite first promising results, where all analyzed 
HDACs (-4, -7, -8) affected proliferation of TNBC cells, HDAC4 and -7 loss did not 
switch cellular phenotype from mesenchymal to epithelial state. Additionally, inhibition 
of HDAC4 and -7 with or without chemotherapy combination did not synergize. Instead, 
among HDACs, the most promising anticancer target in TNBC seems to be HDAC8. 
Loss of HDAC8 activity lead to proliferation impairment in mouse and human TNBC, in 
vitro, that was also shown in neuroblastoma (Rettig et al., 2015). In our project we used 
PCI-34051 as a commercially available selective HDAC8 inhibitor, that is 
recommended for T-cell lymphoma and leukemia cells (Balasubramanian et al., 2008). 
Interestingly it showed cell survival impairment alone and increased sensitivity in 
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combination with CAF-chemotherapy treatment. It would be intriguing to validate this 
effect in combination with other chemotherapy agents, like paclitaxel and cisplatin, 
where EMT regulation was increased even more than in the case of CAF. We could 
observe that only HDAC8 loss but not HDAC4 or HDAC7 loss regulated EMT state. For 
further studies one could determine what are the EMT changes upon HDAC8 inhibition 
in combination with chemotherapy treatment. Nowadays, pan-HDACs inhibitors are the 
most commonly studied (Singh et al., 2018). Despite the promising in vitro and in vivo 
studies, inhibiting most of the HDAC family can bring unwanted side effects among 
patients (Subramanian et al., 2010). The development of selective HDAC inhibitors is 
a key issue in the clinic. The results of our study support the hypothesis that HDAC8 
inhibitor could represent a promising approach to sensitize or re-sensitize TNBCs to 
conventional cytotoxic anti-cancer therapies, where therapy options are limited.  
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5. General discussion  
5.1. PRC2/EZH2 in TNBC progression 
 More than 80% of breast cancer cases can be resected surgically, with 50% 
chance of cancer relapse among those patients (World Health Organization, 2006). 
Surgery can be followed by adjuvant chemotherapy to prevent cancer recurrence. 
Triple-negative breast cancer (TNBC) lacks targeted therapy options, consequently we 
wanted to elucidate TNBC invasion pathways upon chemotherapy as it is one of the 
most common therapy in TNBC patients (Wahba & El-Hadaad, 2015). In this project 
we are focused on TNBC, however similar mechanism of cancer cell escape due to 
chemotherapy treatment can be found in other cancers. Therefore, we aimed that our 
results could be applied in other cancer systems.  
Cytotoxic stimuli enhances epigenetic alterations to gain self-renewal, 
mesenchymal and metastatic properties in tumor cells (Easwaran, 2014). In many 
studies, it was shown that PRC2/EZH2 plays a critical role in cancer progression and 
metastasis. Unsurprisingly, series of small molecule inhibitors of EZH2 have been 
developed. The methyltransferase EZH2 with its catalytic SET domain, transfers a 
methyl group from methyl donor, SAM (S-adenosyl-methionine) to lysine 27 on Histone 
H3 (H3K27). EZH2 inhibitors, blocking its SET domain, such as EPZ-6438, 
GSK2816126 and CPI-1205 are used, among others in phase II clinical trials in non-
Hodgkin lymphoma (Gulati, 2018). However, EZH2-inhibition-based clinical trials can 
result in therapeutic response failure ( NCT02082977 , 2019), necessitating a greater 
attention for anti-EZH2 therapeutic approaches, maximizing benefits for cancer 
patients. In our project, CAF-chemotherapy leads to an epigenetic dysregulation in 
TNBC cells. To our surprise, we observed unexpected PRC2 components loss favoring 
better survival of TNBC cells. Growing number of studies confirm our data, resulting in 
raising concerns about EZH2 as anti-cancer target. (Völkel et al., 2015).  
To this date, TNBC patient cases remain a huge challenging clinic hurdle. Many 
trials on patients failed after EZH2 inhibition therapy. Treatment of some patients with 
Non-Hodgkin Lymphoma (NHL) during Phase I clinical trial, with EPZ6438 (small 
molecule EZH2 inhibitor) resulted in cancer recurrence (Italiano et al., 2018). In 
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malignant myeloid diseases, loss-of-function EZH2 mutations were identified. They 
determined that loss of EZH2 and reduced H3K27me3 level were associated with 
neoplastic disorders and leukemia progression (Muto et al., 2013). Interestingly, in 
hypoxic conditions, hypoxia-inducible factor 1 (HIF1-α) induction leads to PRC2 
inactivation. Released EZH2 from the complex, cooperates with Forkhead box M1 
(FoxM1) leading to direct MMPs promoters regulation and TNBC invasion (Mahara et 
al., 2016) 
TNBC shares molecular similarities with high-grade serous ovarian tumors (Bell 
et al., 2011; Wang et al., 2012). Based on TCGA data, both display frequent p53 
mutations, BRCA1 inactivation, RB1 loss and cMYC amplification correlating with 
TNBC features. We observed that upon EZH2 inhibition TNBC cancer cells can 
progress and induce an even worse prognosis than before treatment. In our studies we 
show similar cell behavior of TNBC (pG-2 and MDA-MB-468) cells such as in colon 
cancer (HCT116 and HT-29) and bile duct (EGI-1 and TFK-1) carcinoma cell lines, 
where EZH2 inhibition lead to better cell growth. As we presented, TCGA-based data 
on TNBC patients indicates low survival rate in cancers with low EZH2 expression. 
Thus, it seems that the regulation through PRC2/EZH2 could be subtype-specific or 
context-dependent. Those data suggest a novel strategy in the treatment finding: it is 
indeed attractive to hypothesize that the same or very similar molecular patterns within 
cancers or their subtypes, could offer common clinical approach for category of patients 







Figure 12:  A scheme of the patients with distinct cancer types but similar treatment strategy and 
response. Orange indicates patient with common anti-cancer therapy strategy, grey reflects the patient 
with response to different anti-cancer treatment. Selected population of patients with distinct cancers 
benefited from the same clinical approach (orange, right). 
5.2. NFATc1 as a potential PRC2/EZH2-dependent driver of TNBC progression 
PRC2/EZH2-dependent activity is an important mechanism to repress gene 
transcription. Our data shows that PRC2/EZH2 is downregulated upon chemotherapy. 
Under cytotoxic stimuli, decreased PRC2/EZH2 activity is likely to lead to the activation 
of previously repressed genes, being crucial for cancer cell fate. Loss of H3K27me3 
and gain of H3K27ac on promoter regions can directly activate targeted genes 
(Grimaldi et al., 2011). As chemotherapy is the most common way to treat TNBC 
displaying the highest response rate among breast cancer patients, we wanted to 
explore the mechanism that drive cell survival followed by chemotherapy. We identified 
Nfatc1, Wnt9a, Gli2 and Klf4 as the most relevant PRC2/EZH2-regulated genes that 
could be involved in chemotherapy resistance.  
A number of studies have shown that NFATc1 favors cancer progression. For 
instance, overexpression or constitutively active NFATs are commonly linked with 
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cancer progression involving angiogenesis and migration (Qin et al., 2014). The 
NFAT/calcineurin pathway is associated with increased invasion of mammary tumor 
cells (Yoeli-Lerner et al., 2009), as seen also in our TNBC system. Interestingly, breast 
cancer subtype-based gene expression analysis revealed that NFAT-related pathway 
is more frequent in TNBC in comparison to non-TNBC patients (Tran Quang et al., 
2015). In our study, we showed that EZH2 is negatively correlated with NFATc1 in vitro 
and in vivo. NFATc1 loss lead to impaired cell proliferation and migration in our WAP-
T in vitro system, indicating the involvement of NFATc1 in TNBC progression. 
Additionally, cell death in human TNBC cell line upon NFATc1 depletion suggests that 
NFATc1 plays essential role in cancer survival. In our data, we observed enrichment 
for calcineurin pathway in CAF-treated cells involving deregulation of NFATc1.  
Intriguingly, NFATc1 was found as a promising anti-leukemia target. For 
instance, in Chronic Lymphocytic Leukemia (CLL), CsA- and FK-506-mediated 
NFATc1 inhibition induced apoptosis of CLL cells (Wolf et al., 2014). In Acute Myeloid 
Leukemia (AML) NFATc1 was proposed as a therapeutic target to overcome resistance 
(Metzelder et al., 2015). These studies and many other publications regarding blood 
cancers strongly support our results in TNBC (Pham et al., 2010). As mentioned 
previously, PRC2/EZH2 loss-of-function was indicated to enhance cancer progression 
in leukemia and lymphoma. This finding brings a potential into therapy of blood cancers 
and TNBC, where PRC2/EZH2-mediated NFATc1 regulation could play fundamental 
role in overcoming cancer progression (Figure 13).  
Based on our results, PRC2/EZH2-dependent NFATc1 regulation can modulate 
cancer cell behavior through EMT. In previous studies, using the WAP-T model in vivo 
and in vitro, TGF-ß pathway activation was shown to increase aggressiveness of WAP-
T tumor cells by inducing EMT (Maenz et al., 2015). Moreover, the group of Hessmann 
demonstrated a synergy between NFATc1 and TGFß1 signaling inducing pancreatic 
cancer progression by inhibiting apoptosis and growth arrest (Hasselluhn et al., 2019). 
TGFß1 signaling is also increased upon CAF treatment of G-2 cells (RNA-seq 
analyses, data not shown). It can be therefore hypothesized that both pathways 
cooperate with each other to stimulate cancer cell survival. Further studies would be 
necessary to prove this idea. In our studies, we determined that NFATc1 activity 
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contributes to the more mesenchymal cell properties. Loss or inhibition of NFATc1 
reversed this process, resulting in an increased epithelial cell fraction. These results 
are in line with former observations that NFATc1 is involved in the regulation of 
epithelial-to-mesenchymal plasticity and stemness (Gould et al., 2016) It is therefore 
tempting to speculate that reversal of an invasive phenotype via NFAT inhibition may 




Figure 13: PRC2/EZH2 downregulation upon CAF-chemotherapy or EPZ-6438 treatment leading to loss 
of H3K27me3 and gain of H3K27ac activating NFATc1. 
 
5.3. Gli2, Klf4, Wnt9a in cancer 
 Apart of NFATc1, other factors were identified as being under control of the 
PRC2 repressive activity. One of these is Gli2, a transcription factor involved in 
hedgehog (Hh) pathway (Méthot & Basler, 2001). Many studies support contribution of 
Hh signaling in cancer progression (Cannonier et al., 2016; D. Huang et al., 2018; N. 
Li et al., 2018). Gli2 leads to increased invasiveness, migration, angiogenesis and drug 
resistance in breast cancer (Atwood et al., 2015; Gupta et al. 2015; Han et al., 2016). 
Interestingly, its the most significant pro-tumorigenic function was reported in TNBC 
(Habib & O’Shaughnessy, 2016).  Gli2 is potential PRC2/EZH2-mediated factor 
involved in TNBC progression. Hh along with Wnt and TGF‐β signaling contributes to 
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EMT and increased stemness capacity in breast, ovarian and pancreatic cancer (Morel 
et al., 2008; Noubissi et al., 2018; Scheel et al., 2011). Additionally, the Hh pathway is 
associated with drug resistance where its enrichment was observed in cancer cells 
resistant to paclitaxel and doxorubicin (Narita et al., 2008; Zhou et al., 2012). These 
findings support our results and suggest that PRC2-dependent Gli2 regulation could be 
additional or cooperating mechanism with PRC2-NFATc1 pathway leading to TNBC 
cell survival.   
 Together with hedgehog pathway, Wnt/beta-catenin signaling pathway was 
reported to promote cell proliferation and stemness maintenance (Mullor et al., 2001; 
Noubissi et al., 2018). Wnt/beta-catenin can lead to drug resistance and cell immortality 
through upregulation of MMP7 and hTERT, respectively. Wnt9a was identified as a 
major player in colon tumorigenesis (Bhattacharyya, Feferman, & Tobacman, 2014). 
There is no data describing Wnt9a in TNBC progression. However, based on our data 
Wnt9a could be interesting gene candidate to investigate in chemotherapy resistance 
in TNBC.  
 Apart of NFATc1, Gli2 and Wnt9a, we identified Klf4 as a gene regulated upon 
chemotherapy. Kruppel-like factor 4  (Klf4) plays diverse functions in diseases (Ghaleb 
& Yang, 2017). Klf4 activation by loss of EZH2 and H3K27me3 upon cytotoxic stimuli, 
could be one of the players inducing pluripotency of TNBC cells. In Mouse embryonic 
fibroblasts (MEFs), it was identified that calcineurin can be activated via overexpression 
of Klf4 (Khodeer & Era, 2017). In TNBC, calcineurin phosphatase induction could 
potentially dephosphorylate NFATc1 and enhance even more its oncogenic function, 
additionally to PRC2 regulation. 
 
5.4. NFATc1 and HDAC inhibition in TNBC in the clinic 
Our studies indicated NFATc1 (Chapter I) and HDAC8 (Chapter II) as the 
upregulated factors upon chemotherapy treatment in TNBC cells. Based on our 
findings, HDAC8 appears to have prominent role in TNBC progression, where its 
inhibition alone impairs cancer cell growth with sensitization effect upon combination 
with chemotherapy. NFATc1 and HDAC8 are involved in TNBC cancer progression by 
92 
 
promoting EMT. NFATc1 and HDAC8 loss or inhibition leads to decreased proliferation 
growth rate. Subsequently, NFATc1 and HDAC8 inhibition could bring therapeutical 
benefits for TNBC patients. As we showed in our project, HDAC8 inhibition via PCI-
34051 have anti-TNBC potential that was also observed in T-cell lymphomas where 
PCI-34051 treatment induced cell apoptosis (Balasubramanian et al., 2008). 
Additionally, we propose inhibition of HDAC8 in combination with other drug as an 
alternative for cytotoxic pan-HDACs inhibition. Despite several promising pan-HDAC 
inhibitors, FDA-approved or undergoing clinical trials, can give unwanted side effects, 
strongly affecting patient’s life. In contrast, isoform-specific HDAC inhibitor could offer 
impairment of cancer progression with beneficial effect for patient survival. As 
epigenetic mechanisms are reversible, anti-tumorigenic effect of HDAC8 inhibition 
could be used as epigenetic therapy supporting NFATc1 blockade bringing effective 
therapeutic result.  Thus, for further investigation, it would be interesting to check the 
effect of simultaneous inhibition of NFATc1 and HDAC8 that could synergistically impair 
cancer progression. This proposed therapy solution should be limited to particular 
category of patients. As it was discussed previously, in most of the cancers EZH2 was 
indicated as an oncogenic factor. The downregulated PRC2/EZH2 activity as a novel 
mechanism in cancer progression, should be further investigated among cancers. This 
information could imply molecular changes, such as NFAT pathway regulation.  
In our project we propose that upregulation of NFATc1 and HDAC8 in TNBC 
could emerge as essential therapeutic targets. Therefore, selective anticancer drug 
combination involving NFATc1 and HDAC8 inhibition might be suggested as a novel 
anti-TNBC approach for further investigation. 
 
 
In summary, we have investigated the novel landmark in TNBC survival to 
chemotherapy stimuli. We demonstrated that in chemotherapy-treated TNBC cells, loss 
of PRC2/EZH2 leads to NFATc1 activation initiating an EMT process and fostering 
cancer progression (Figure 13). Since many studies have shown critical function of 
NFATc1 in tumor progression, drug resistance and metastasis, NFATc1 inhibition may 
represent a potential strategy to overcome chemotherapy resistance in cancer. 
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Additional investigation on NFATc1 function in TNBC progression will be needed in the 
future. Moreover, examination of the function of other PRC2/EZH2-dependent factors 
(Gli2, Wnt9a, Klf4), their importance in chemotherapy resistance and relationship with 
NFAT pathway could be interesting. Additionally, epigenetic PRC2/EZH2-dependent 
mechanism could potentially interplay with HDACs function inducing pro-tumorigenic 
pathways. Our findings suggest NFATc1 and HDAC8 as major regulators of TNBC 
progression that could be proposed for combinatory therapy, where NFATc1 and 
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